Original Article
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
N Engl J Med 2008; 359:906-917August 28, 2008DOI: 10.1056/NEJMoa0801479
- Abstract
Background
The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy.
Methods
We randomly assigned 682 patients to receive nine 6-week cycles of melphalan (at a dose of 9 mg per square meter of body-surface area) and prednisone (at a dose of 60 mg per square meter) on days 1 to 4, either alone or with bortezomib (at a dose of 1.3 mg per square meter) on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1 to 4 and on days 1, 8, 22, and 29 during cycles 5 to 9. The primary end point was the time to disease progression.
Results
The time to progression among patients receiving bortezomib plus melphalan–prednisone (bortezomib group) was 24.0 months, as compared with 16.6 months among those receiving melphalan–prednisone alone (control group) (hazard ratio for the bortezomib group, 0.48; P<0.001). The proportions of patients with a partial response or better were 71% in the bortezomib group and 35% in the control group; complete-response rates were 30% and 4%, respectively (P<0.001). The median duration of the response was 19.9 months in the bortezomib group and 13.1 months in the control group. The hazard ratio for overall survival was 0.61 for the bortezomib group (P=0.008). Adverse events were consistent with established profiles of toxic events associated with bortezomib and melphalan–prednisone. Grade 3 events occurred in a higher proportion of patients in the bortezomib group than in the control group (53% vs. 44%, P=0.02), but there were no significant differences in grade 4 events (28% and 27%, respectively) or treatment-related deaths (1% and 2%).
Conclusions
Bortezomib plus melphalan–prednisone was superior to melphalan–prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy. (ClinicalTrials.gov number, NCT00111319.)
Media in This Article
Figure 1
Kaplan–Meier Curves for the Time to Disease Progression and Overall Survival (Intention-to-Treat Population).Figure 2
Subgroup Analyses of Time to Disease Progression as Assessed by the Investigators.Article Activity
- Article
Therapy with melphalan plus prednisone, which has been the standard of care for patients with newly diagnosed multiple myeloma for more than 40 years,1,2 is associated with a median survival of 29 to 37 months. 3-6 During the past decade, high-dose therapy with hematopoietic stem-cell transplantation has become the preferred treatment for patients under the age of 65 years,7-9 but older patients and patients with clinically significant coexisting illnesses usually do not tolerate this treatment. Since the median age at diagnosis of myeloma is approximately 70 years,10 more than half the patients with newly diagnosed myeloma may not be eligible for high-dose therapy. For these patients, improved treatment is needed. The proteasome inhibitor bortezomib is active in relapsed or refractory myeloma. 11 On the basis of results of a phase 3 trial,12,13 bortezomib was approved for the treatment of myeloma in patients who had received at least one previous therapy.
In preclinical studies, bortezomib sensitized melphalan-sensitive and melphalan-resistant myeloma cell lines to melphalan and down-regulated cellular responses to genotoxic stress.14,15 In combined phase 1 and 2 trials, bortezomib plus melphalan had encouraging activity in patients with relapsed or refractory myeloma.16 These findings led to a combined phase 1 and 2 trial of bortezomib–melphalan and prednisone in patients with newly diagnosed multiple myeloma who were 65 years of age or older.17,18 The complete-response rate of 32%, the median time to progression of 27 months, and the estimated 38-month survival rate of 85% were improvements over the results in historical control subjects who received only melphalan–prednisone.17,18 Our phase 3 trial compared bortezomib plus melphalan–prednisone with melphalan–prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy.
Methods
Patients
Patients with newly diagnosed, untreated, symptomatic, measurable myeloma who were not candidates for high-dose therapy plus stem-cell transplantation because of age (≥65 years) or coexisting conditions were eligible. Measurable disease was defined as the presence of quantifiable M protein in serum or urine or measurable soft-tissue or organ plasmacytomas. Review boards at all participating institutions approved the study, which was conducted according to the provisions of the Declaration of Helsinki, the International Conference on Harmonization, and the Guidelines for Good Clinical Practice. All patients provided written informed consent.
Study Design and Treatment
This randomized (1:1), open-label, phase 3 study was conducted at 151 centers in 22 countries in Europe, North and South America, and Asia. Patients were recruited from December 2004 to September 2006. They received nine 6-week cycles of melphalan (at a dose of 9 mg per square meter of body-surface area) and prednisone (at a dose of 60 mg per square meter) on days 1 to 4, alone or in combination with bortezomib (at a dose of 1.3 mg per square meter), by intravenous bolus on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1 to 4 and on days 1, 8, 22, and 29 during cycles 5 to 9. The planned 54-week treatment corresponded to the standard duration of melphalan–prednisone therapy. Randomization was stratified according to baseline levels of β2-microglobulin (<2.5, 2.5 to 5.5, or >5.5 mg per liter [<212, 212 to 466, or >466 nmol per liter]), serum albumin (<3.5 or ≥3.5 g per deciliter), and region (North America, Europe, or other region). Treatment was discontinued on withdrawal of the patient's consent, disease progression, or the occurrence of unacceptable toxic effects. The dose of melphalan or bortezomib was reduced if there was any prespecified hematologic toxic effect or grade 3 or 4 nonhematologic toxic effect; bortezomib-associated neuropathic pain and peripheral sensory neuropathy were managed with the use of established dose-modification guidelines.19 Patients with myeloma-associated bone disease received bisphosphonates, unless such therapy was contraindicated.20
The primary end point was the time to disease progression. Prespecified secondary end points included the rate of complete response, the duration of response, the time to subsequent myeloma therapy, and overall survival. (Additional prespecified secondary end points are described in the Supplementary Appendix, available with the full text of this article at www.nejm.org.) The trial was designed by the senior academic authors, in collaboration with Johnson & Johnson Pharmaceutical Research & Development and Millennium Pharmaceuticals. Data were collected by the sponsors and analyzed in collaboration with the senior academic authors, who vouch for the completeness and accuracy of the data and the analyses. The first draft of the manuscript was developed by the senior academic investigators with editorial assistance from representatives of Johnson & Johnson Pharmaceutical Research & Development. Additional writing assistance was provided by both sponsors.
Assessments
We assessed the response to treatment using criteria of the European Group for Blood and Marrow Transplantation (EBMT)21 and a prespecified computer algorithm that was validated in a previous trial.13 In a post hoc analysis, we assessed the response by applying an algorithm to implement the International Uniform Response Criteria for Multiple Myeloma.22 Disease progression was determined by EBMT criteria. These criteria included relapse from complete response, which was defined as the reappearance of M protein on immunofixation. Investigators assessed progression on the basis of analyses of M protein in serum and urine that were performed by a central laboratory and other factors described below. Investigators provided the sponsors with documentation supporting the diagnosis of progressive disease, which was reviewed in real time for consistency with EBMT criteria.21 The sponsors also determined progression with the use of a computer algorithm that applied EBMT criteria. Data presented here include assessments performed both by the investigators and by algorithmic analysis.
Blood and 24-hour urine samples were collected every 3 weeks during the 54-week treatment phase and then every 8 weeks until disease progression. Other efficacy assessments included bone marrow examination and skeletal survey as required by EBMT criteria21 or in cases in which such assessment was clinically required or indicated on the basis of measurement of extramedullary plasmacytomas or analysis of corrected serum calcium levels.
Patients were followed for survival and subsequent myeloma therapy at least every 12 weeks after disease progression. Safety was evaluated throughout the study and until 30 days after the administration of the last dose of a study drug. Adverse events were graded with the use of the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0. Serious adverse events were monitored monthly by the independent data and safety monitoring committee.
Statistical Analysis
We analyzed the time to progression, the time to subsequent myeloma therapy, and overall survival from randomization and compared the differences between groups using stratified log-rank tests in the intention-to-treat population (all randomized patients). Distributions were estimated with use of the Kaplan–Meier method. For time-to-progression analyses, data from patients in whom there was no disease progression were censored at the last assessment or at the start of subsequent therapy. Hazard ratios were estimated with the use of the stratified Cox proportional-hazards model for the intention-to-treat population, as well as within subgroups that were defined according to baseline characteristics in order to assess the consistency of treatment effects (seven prespecified analyses according to age, sex, race, baseline β2-microglobulin level, baseline albumin level, region, and disease stage and one post hoc analysis according to creatinine clearance).
Response rates were analyzed in the population of patients who could be evaluated for a response and were compared between groups on the basis of a stratified Cochran–Mantel–Haenszel chi-square test. The efficacy of bortezomib plus melphalan–prednisone was assessed post hoc within subgroups that were defined as having a poor prognosis on the basis of age (≥75 years), an impaired creatinine clearance (<60 ml per minute), or a high-risk cytogenetic profile — the presence of a t(4;14),t(14;16) translocation or a 17p deletion — on the basis of fluorescence in situ hybridization performed at local study sites. Safety was analyzed in all patients who underwent randomization and received at least one dose of a study drug.
Treatment differences were tested at a two-sided alpha level of 0.05. We determined that a sample size of 340 patients per group would provide a power of 80% to detect a 33% improvement in the time to progression in patients receiving bortezomib plus melphalan–prednisone, as compared with those receiving melphalan–prednisone alone. We planned three interim analyses using the O'Brien–Fleming method.23 On the basis of the third analysis (with a data cutoff of June 15, 2007), the data and safety monitoring committee recommended that the study be stopped, since the prespecified statistical boundary (an alpha level of 0.0108) for the primary end point of time to progression had been crossed (hazard ratio in the bortezomib group, 0.54; P<0.001). Data from the third analysis are presented.
Results
Patients and Treatment
From a total of 682 patients who were enrolled, we randomly assigned 344 patients to receive bortezomib plus melphalan–prednisone (bortezomib group) and 338 to receive only melphalan–prednisone (control group) (Fig. 1 in the Supplementary Appendix). Baseline demographic and disease characteristics were well balanced between the two groups (Table 1Table 1
Baseline Characteristics of the Patients.). Among the study patients, 30% were 75 years of age or older, 33% had a β2-microglobulin level of more than 5.5 mg per liter (>466 nmol per liter), and 10% reported having grade 1 peripheral sensory neuropathy before treatment. At the data cutoff point, 47 patients (14%) in the bortezomib group and 33 patients (10%) in the control group were still receiving the assigned protocol therapy.Efficacy
The median time to progression on the basis of data from the central laboratory, as assessed by the investigators, was 24.0 months in the bortezomib group and 16.6 months in the control group (hazard ratio in the bortezomib group, 0.48; P<0.001) (Figure 1AFigure 1
Kaplan–Meier Curves for the Time to Disease Progression and Overall Survival (Intention-to-Treat Population).). The time-to-progression benefit in the bortezomib group was independent of age, sex, race, baseline β2-microglobulin level, baseline albumin level, geographic region, clinical stage (on the basis of the International Staging System24), or creatinine clearance (Figure 2Figure 2Subgroup Analyses of Time to Disease Progression as Assessed by the Investigators.).The response could be evaluated in 337 patients in the bortezomib group and 331 in the control group. The rates of partial response or better (according to EBMT criteria) were 71% in the bortezomib group as compared with 35% in the control group (P<0.001), and the complete-response rates were 30% and 4%, respectively (P<0.001) (Table 2Table 2
Best Response to Treatment and Time-to-Event Data.). In the post hoc analysis of response according to the International Uniform Response Criteria, the rates of complete response were 33% and 4% in the bortezomib group and the control group, respectively (Table 2). Of the 79 patients in the bortezomib group who were considered to have stable disease on the basis of the International Uniform Response Criteria, 4 had negative results on immunofixation, and 19 had a reduction in the M protein level in serum or urine of 50% or more. However, these patients were not recorded as having had a complete or partial response, since they did not fulfill some aspects of the International Uniform Response Criteria, mainly because the confirmatory test results were missing. An additional 38 patients had a reduction in M protein of 25 to 49% or met the requirements for a minimal response, according to EBMT criteria for nonsecretory disease.The median duration of a response (according to EBMT criteria) was 19.9 months in the bortezomib group and 13.1 months in the control group; the median duration of response among patients who had a complete response was 24.0 months in the bortezomib group and 12.8 months in the control group. The median time to subsequent therapy and the associated treatment-free interval were significantly longer in the bortezomib group than in the control group, with 35% and 57% of patients, respectively, starting second-line treatment within 2 years (Table 2, and Fig. 2B in the Supplementary Appendix). Of 121 patients in the control group who received subsequent therapy, 54 (45%) received therapy that included bortezomib.
After a median follow-up of 16.3 months, 45 patients (13%) in the bortezomib group and 76 patients (22%) in the control group had died (hazard ratio in the bortezomib group, 0.61, P=0.008); median survival was not reached in either group (Figure 1B).
We also assessed the efficacy of bortezomib therapy in three subgroups of patients who had a poor prognosis. In 107 patients who were 75 years of age or older, as compared with 237 younger patients, the median time to progression was identical, the rate of complete response (according to EBMT criteria) was slightly lower (26% vs. 32%, P=0.29), and median overall survival was slightly shorter (P=0.17). The 185 patients with impaired renal function (creatinine clearance, <60 ml per minute) did not differ significantly from the 159 patients with normal renal function (creatinine clearance, ≥60 ml per minute) with respect to the complete-response rate (28% and 32%, respectively), the time to progression (P=0.09), or the overall rate of survival (P=0.99). The 26 patients with high-risk cytogenetic profiles — including the presence of a t(4;14),t(14;16) translocation or a 17p deletion — and the 142 patients with standard cytogenetic profiles had the same rate of complete response (28%), with similar times to progression (P=0.55) and overall survival (P=0.99). The results remained similar with the inclusion of 75 patients with a 13q deletion in the high-risk group (data not shown). Time-to-progression and survival curves for these subgroups are shown in Fig. 3 in the Supplementary Appendix.
Adverse Events
The median number of treatment cycles administered was 8 (46 weeks) in the bortezomib group and 7 (39 weeks) in the control group. The median dose intensities for melphalan and prednisone were the same in the two groups (99% or more of those expected). The bortezomib group and the control group did not differ significantly with respect to rates of death during treatment (5% and 4%, respectively) or treatment-related death (1% and 2%).
Table 3Table 3
Adverse Events (Safety Population). lists the most common adverse events overall and grade 3 or 4 events; also listed are adverse events that had specific clinical relevance. Hematologic toxic effects were similar in the two groups. Peripheral sensory neuropathy was reported more frequently in the bortezomib group, including grade 1 neuropathy in 49 patients (14%), grade 2 in 58 patients (17%), grade 3 in 43 patients (13%), and grade 4 in 1 patient (<1%). At the time of data cutoff, 74% of peripheral-neuropathy events had either resolved (56%) or decreased by at least one toxicity grade (18%) within a median of 2 months. All grade 3 or 4 gastrointestinal symptoms were more frequent in the bortezomib group than in the control group (19% vs. 5%), as was any grade of herpes zoster (13% vs. 4%); the incidence of herpes zoster was reduced to 3% in patients in the bortezomib group who were receiving antiviral prophylaxis. Incidences of grade 3 or 4 pneumonia and deep-vein thrombosis were low and similar in the two groups (Table 3).The rate of serious adverse events in the bortezomib group was higher than that in the control group (46% vs. 36%). Fifty patients (15%) in the bortezomib group and 47 patients (14%) in the control group discontinued treatment because of adverse events, including 37 patients (11%) and 35 patients (10%), respectively, who had treatment-related events. Bortezomib alone was discontinued in an additional 63 patients (19%).
Discussion
This phase 3 study showed that the addition of bortezomib to melphalan–prednisone was associated with significant improvement in outcomes in patients with newly diagnosed myeloma who were ineligible for high-dose therapy. The median time to progression (the primary end point) was 7.4 months longer in the bortezomib group than in the control group (hazard ratio, 0.48; P<0.001). This benefit was seen across all subgroups of patients, as defined according to baseline demographic and disease characteristics.
There were significant improvements associated with bortezomib therapy for all prespecified secondary end points, including the rate of complete response (according to EBMT criteria), the time to subsequent myeloma therapy, and overall survival. The response was more rapid and durable in the bortezomib group than in the control group. In the bortezomib group, the median time to a complete response was longer than the median time to the first response (Table 2), suggesting that prolonged treatment might improve the quality of the response, as was reported for patients with relapsed myeloma who were receiving bortezomib alone.12 The complete-response rate of 30% (according to EBMT criteria) that was associated with bortezomib was substantial in phase 3 trials involving patients with myeloma who were 65 years of age or older.25-27 Among patients in the bortezomib group who had a complete response, the median duration of the response was 24 months. In the bortezomib group, the longer time to subsequent therapy was associated with a prolonged treatment-free interval, which may represent an added value for patients. At a median follow-up of 16.3 months, 45 patients in the bortezomib group and 76 in the control group had died (hazard ratio in the bortezomib group, 0.61; P=0.008), indicating a survival benefit associated with bortezomib, despite the finding that 45% of patients in the control group received subsequent therapy that included bortezomib after disease progression.
Superior efficacy in the treatment of myeloma has now been shown with bortezomib or thalidomide25-27 in combination with melphalan and prednisone. Therefore, melphalan and prednisone alone can no longer be considered the standard of care in patients who are 65 years of age or older. Data from a combined phase 1 and 2 trial have also suggested that lenalidomide plus melphalan–prednisone has clear antimyeloma activity.28 It would not be appropriate to compare the results of our trial with phase 3 studies of thalidomide because of confounding differences in study populations (e.g., age), the duration of therapy, the use of maintenance therapy, and especially the methodology and criteria used for definitions of response and progression.29,30 Our study included assessment every 3 weeks, measurement of the time to events starting at randomization, and the use of EBMT criteria. The effect of methodologic differences is apparent within the bortezomib group: the median time to progression as assessed by investigators (24.0 months) was 3 months longer than that as assessed by algorithmic analysis and was not reached at 27 months in a post hoc analysis on the basis of a previously described modification of the International Uniform Response Criteria.25
The adverse events reported in the bortezomib group were consistent with established toxicity profiles for both bortezomib11,13,31 and melphalan–prednisone.4,6 The rate of death during treatment was low in both groups, as compared with historical data on early mortality among elderly patients.32,33 The rate of peripheral sensory neuropathy in the bortezomib group was consistent with the rate reported in previous studies, taking into account the duration of therapy and the cumulative dose of bortezomib.17,34 After only 16.3 months of follow-up, peripheral neuropathy improved or resolved in most patients, confirming that prompt modification of the bortezomib dose according to established guidelines19 is important to avoid severe neurotoxicity and ensure reversibility. Hematologic toxic effects were similar in the two groups, and the incidence of deep-vein thrombosis was very low in both groups, even though the protocol did not require prophylaxis.
In conclusion, this study showed that bortezomib plus melphalan–prednisone was superior to melphalan–prednisone alone for the treatment of patients with newly diagnosed myeloma who were ineligible for high-dose therapy, although bortezomib was associated with a slightly higher rate of adverse events. Our findings suggest that bortezomib plus melphalan–prednisone is a valuable front-line treatment for patients with myeloma who are 65 years of age or older and cannot receive more aggressive treatment.35
Presented in part at the annual meeting of the American Society of Hematology, Atlanta, December 10, 2007.
Supported by Johnson & Johnson Pharmaceutical Research & Development and Millennium Pharmaceuticals.
Dr. San Miguel reports receiving consulting and lecture fees from Ortho Biotech, Millennium Pharmaceuticals, Celgene, and Pharmion; Dr. Dimopoulos, consulting and lecture fees from Celgene, Ortho Biotech, Pharmion, and Novartis; Dr. Kropff, consulting fees from Ortho Biotech, Celgene, and Pharmion and lecture fees from Ortho Biotech; Dr. Spicka, lecture fees from Novartis; Dr. Palumbo, consulting and lecture fees from Janssen Cilag; Dr. Schots, consulting fees from Pharmion and Celgene and lecture fees from Celgene; Dr. Mateos, consulting and lecture fees from Ortho Biotech; Dr. Anderson, consulting and lecture fees from Celgene, Millennium Pharmaceuticals, and Novartis; Dr. Esseltine, being an employee of and holding an equity interest in Millennium Pharmaceuticals; Drs. Liu, Cakana, and van de Velde, being employees of and having an equity interest in Johnson & Johnson Pharmaceutical Research and Development; and Dr. Richardson, receiving consulting and lecture fees from Millennium Pharmaceuticals and lecture fees from Celgene. No other potential conflict of interest relevant to this article was reported.
We thank the patients who volunteered to participate in this study and staff members at the study sites who cared for them; the members of the data and safety monitoring committee: Robert Kyle (chair), Donna E. Reece, Gareth Morgan, and Thomas Fleming; representatives of the sponsors who were involved in data collection and analyses (in particular, Martine Bayssas, Gang Chen, Suzanne Viselli, and William Deraedt); and Namit Ghildyal (of Johnson & Johnson Pharmaceutical Research & Development), Steve Hill, and Jane Saunders for their assistance in the preparation of the manuscript.
Source Information
The authors' affiliations are listed in the Appendix.
Address reprint requests to Dr. San Miguel at Hospital Universitario de Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain, or at sanmigiz@usal.es.
Investigators in the Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone (VISTA) trial are listed in the Appendix.
Appendix
The authors' affiliations are as follows: Hospital Universitario Salamanca, CIC, IBMCC (USAL-CSIC), Salamanca, Spain (J.F.S.M., M.-V.M.); Praxisklinik Dr. Schlag, Würzburg, Germany (R.S.); S.P. Botkin Moscow City Clinical Hospital, Moscow (N.K.K.); University of Athens School of Medicine, Athens (M.A.D.); Rabin Medical Center, Petah-Tiqva, Israel (O.S.); University of Münster, Münster, Germany (M.K.); University Hospital, Prague, Czech Republic (I.S.); University La Sapienza, Rome (M.T.P.); Universita di Torino, Turin, Italy (A.P.); Nizhnii Novgorod Region Clinical Hospital, Nizhnii Novgorod, Russia (O.S.S.); Medical University of Lublin, Lublin, Poland (A.D.); St. Petersburg Clinical Research Institute of Hematology and Transfusiology, St. Petersburg, Russia (K.M.A.); Myeloma Study Group, Belgian Hematological Society, Brussels (R.S.); People's Hospital, Peking University, Beijing (B.J.); Dana–Farber Cancer Institute, Boston (K.C.A., P.G.R.); Millennium Pharmaceuticals, Cambridge, MA (D.L.E.); and Johnson & Johnson, Raritan, NJ (K.L.), and Beerse, Belgium (A.C., H.V.).
In addition to the authors, the following investigators (listed in alphabetical order) participated in the study: Argentina: C. Corrado (Buenos Aires), D. Fantl (Buenos Aires), J. Garcia (Cordoba), G. Klein (La Plata), D. Riveros (Buenos Aires); Australia: R. Hermann (Perth), M. Hertzberg (Westmead), N. Horvath (Adelaide), P. Marlton (Woolloongabba), A. Spencer (Melbourne); Austria: J. Drach (Vienna), H. Gisslinger (Vienna), R. Greil (Salzburg), E. Gunsilius (Innsbruck), W. Linkisch (Graz), A. Petzer (Linz), J. Thaler (Wels); Belgium: M. Andre (Charleroi), Y. Beguin (Liège), D. Bron (Brussels), H. Demuynck (Roeselare), B. De Prijck (Liège), M. Delforge (Leuven), C. Doyen (Mont Godinne), A. Ferrant (Brussels), W. Feremans (Brussels), A. Janssens (Ghent), A. Van de Velde (Antwerp), J. Van Droogenbroeck (Bruges), P. Vermeulen (Verviers), P. Zachee (Antwerp); Canada: N. Bahlis (Calgary), A. Belch (Edmonton), S. Dolan (St. John), S. Fox (Greenfield Park), A. Lavoie (Quebec City), M. Voralia (Saskatoon); China: H. Ai (Beijing), J. Hou (Shanghai), F. Meng (Guangzhou), Z. Shen (Shanghai), Y. Zhao (Beijing); Czech Republic: R. Hajek (Brno), V. Maisnar (Hradec Kralove); Finland: E. Koivunen (Tampere), K. Remes (Turku), A. Sikiö (Jyväskylä), S. Vanhatalo (Pori); France: M. Attal (Toulouse), J. Harousseau (Nantes), C. Hulin (Nancy), M. Michallet (Lyon), G. Salles (Benite); Germany: H. Durk (Hamm), M. Engelhardt (Freiburg), C. Gabor (Cologne), H. Goldschmidt (Heidelberg), M. Haenel (Chemnitz), G. Hess (Mainz), W. Knauf (Frankfurt), M. Schlag (Würzburg), M. Welslau (Aschaffenburg); Greece: K. Zervas (Thessaloniki), N. Zoumbos (Patras); Hungary: Z. Borbényi (Szeged), S. Fekete (Budapest), A. Illes (Debrecen), T. Masszi (Budapest); G. Radvanyi (Miskolc), G. Tarkovacs (Budapest); Israel: D. Ben-Yehuda (Jerusalem), A. Berrebi (Rechovot), A. Nagler (Ramat-Gan), J. Rowe (Haifa); Italy: M. Boccadoro (Turin), M. Cavo (Bologna), P. De Fabritiis (Rome), R. Foa (Rome), M. Lazzarino (Pavia), A. Liberati (Perugia), E. Morra (Milan), P. Musto (San Giovanni Rotondo), A. Pinto (Naples); Korea: K. Kim (Seoul), C. Min (Seoul), Y. Min (Seoul), C. Suh (Seoul), S. Yoon (Seoul); New Zealand: S. Gibbons (Christchurch); Poland: A. Hellmann (Gdansk), J. Holowiecki (Katowice), J. Kloczko (Bialystok), K. Kuliczkowski (Wroclaw), M. Komarnicki (Poznan), T. Robak (Łódź), K. Sulek (Warsaw); Russia: J. Alexeeva (St. Petersburg), M. Biakhov (Moscow), N. Domnikova (Novosibirsk), Y. Dunaev (Arkhangelsk), G. Gaisarova (Ufa), A. Golenkov (Moscow), A. Loginov (Ekaterinburg), V. Patrin (Volgograd), V. Pavlov (Obninsk), V. Rossiev (Samara), O. Rukavitsyn (Moscow), V. Savchenko (Moscow), A. Suvorov (Izhevsk), V. Yablokova (Yaroslavl); Spain: A. Alegre (Madrid), J. Bladé (Barcelona), J. De La Rubia (Valencia), J. Diaz-Mediavilla (Madrid), J. Hernandez (Segovia), L. Palomera (Zaragoza), A. Sureda (Barcelona); Sweden: B. Björkstrand (Stockholm), A. Gruber (Stockholm); Taiwan: T. Chao (Taipei), S. Huang (Taipei), C. Kuan-Der Lee; (Chiayi Hsien), C. Kuo (Kaohsiung), L. Shih (Tayuan); United Kingdom and Ireland: J. Cavet (Manchester), M. Kazmi (London), T. Littlewood (Oxford), M. O'Dwyer (Galway), S. Rule (Plymouth), N. Russell (Nottingham); United States: J. Berdeja (Loma Linda, CA), D. Bruetman (Goshen, IN), F. Butler (Indianapolis), N. Callander (Madison, WI), J. Glass (Shreveport, LA), J. Gurtler (Metairie, LA), W. Hanna (Knoxville, TN), C. Holladay (Charleston, SC), D. Irwin (Berkeley, CA), R. Lewis (Lake Charles, LA), V. Morrison (Minneapolis), S. Noga (Baltimore), T. Roberts (New Orleans), G. Schiller (Los Angeles).
- References
References
1
Alexanian R ,Haut A ,Khan AU , et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969;208:1680-1685
CrossRef | Web of Science | Medline2
Kyle RA ,Rajkumar SV . Multiple myeloma. N Engl J Med 2004;351:1860-1873[Erratum, N Engl J Med 2005;352:1163.]
Full Text | Web of Science | Medline3
Boccadoro M ,Marmont F ,Tribalto M , et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991;9:444-448
Web of Science | Medline4
Facon T ,Mary JY ,Pegourie B , et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292-1298
CrossRef | Web of Science | Medline5
Myeloma Trialists' Collaborative Group
Web of Science | Medline6
Hernandez JM ,Garcia-Sanz R ,Golvano E , et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004;127:159-164
CrossRef | Web of Science | Medline7
Attal M ,Harousseau JL ,Stoppa AM , et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97
Free Full Text | Web of Science | Medline8
Barlogie B ,Jagannath S ,Vesole DH , et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-793
Web of Science | Medline9
Child JA ,Morgan GJ ,Davies FE , et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883
Free Full Text | Web of Science | Medline10
Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2002. Bethesda, MD: National Cancer Institute, 2005.
11
Richardson PG ,Barlogie B ,Berenson J , et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617
Free Full Text | Web of Science | Medline12
Richardson PG ,Sonneveld P ,Schuster M , et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-3560
CrossRef | Web of Science | Medline13
Richardson PG ,Sonneveld P ,Schuster MW , et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498
Free Full Text | Web of Science | Medline14
Mitsiades N ,Mitsiades CS ,Richardson PG , et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-2380
CrossRef | Web of Science | Medline15
Ma MH ,Yang HH ,Parker K , et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-1144
Web of Science | Medline16
Berenson JR ,Yang HH ,Sadler K , et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937-944
CrossRef | Web of Science | Medline17
Mateos MV ,Hernandez JM ,Hernandez MT , et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006;108:2165-2172
CrossRef | Web of Science | Medline18
Mateos MV ,Hernandez JM ,Hernandez MT , et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008;93:560-565
CrossRef | Web of Science | Medline19
Richardson PG ,Briemberg H ,Jagannath S , et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-3120
CrossRef | Web of Science | Medline20
Kyle RA ,Yee GC ,Somerfield MR , et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-2472
CrossRef | Web of Science | Medline21
Blade J ,Samson D ,Reece D , et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-1123
CrossRef | Web of Science | Medline22
Durie BG ,Harousseau JL ,Miguel JS , et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473[Erratum, Leukemia 2006;20:2220, 2007;21:1134.]
CrossRef | Web of Science | Medline23
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline24
Greipp PR ,San Miguel J ,Durie BG , et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420[Erratum, J Clin Oncol 2005;23:6281.]
CrossRef | Web of Science | Medline25
Facon T ,Mary JY ,Hulin C , et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-1218
CrossRef | Web of Science | Medline26
Palumbo A ,Bringhen S ,Caravita T , et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-831
CrossRef | Web of Science | Medline27
Hulin C ,Facon T ,Rodon P , et al. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood 2007;110:11a-11a28
Palumbo A ,Falco P ,Corradini P , et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-4465
CrossRef | Web of Science | Medline29
Richardson PG ,Niesvizky R ,Anderson KC ,Blade J . Re: When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2008;100:373-373
Web of Science | Medline30
Panageas KS ,Ben-Porat L ,Dickler MN ,Chapman PB ,Schrag D . When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007;99:428-432
CrossRef | Web of Science | Medline31
Jagannath S ,Barlogie B ,Berenson J , et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-172
CrossRef | Web of Science | Medline32
Anagnostopoulos A ,Gika D ,Symeonidis A , et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol 2005;75:370-375
CrossRef | Web of Science | Medline33
Augustson BM ,Begum G ,Dunn JA , et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 -- Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219-9226
CrossRef | Web of Science | Medline34
San Miguel JF ,Richardson P ,Sonneveld P , et al. Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood 2005;106:111a-111a
Web of Science35
Anderson KC ,Kyle RA ,Rajkumar SV ,Stewart AK ,Weber D ,Richardson P . Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008;22:231-239
CrossRef | Web of Science | Medline
- Citing Articles (459)
Citing Articles
1
Jutta Auberger, Stefan Vogt, Georg Hopfinger, Johannes Clausen, Richard Greil. (2013) Topical evening primrose oil for reduction of bortezomib-induced skin reactions. Annals of Hematology 92:7, 995-996
2
Zhiyong Zeng, Junfang Lin, Junmin Chen. (2013) Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Annals of Hematology 92:7, 935-943
3
J. L. Warner, G. Alterovitz, K. Bodio, R. M. Joyce. (2013) External phenome analysis enables a rational federated query strategy to detect changing rates of treatment-related complications associated with multiple myeloma. Journal of the American Medical Informatics Association 20:4, 696-699
4
S. Adami, C. Alberti, G. Scroccaro. (2013) Analisi critica di un campione di farmaci oncologici valutati dalla Commissione Tecnica Regionale della Regione Veneto. Giornale Italiano di Health Technology Assessment
5
Oliver Planz. (2013) Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Research 98:3, 457-468
6
Elisabeth G. Vichaya, Xin Shelley Wang, Jessica A. Boyette-Davis, Tito R. Mendoza, Zijing He, Sheeba K. Thomas, Nina Shah, Loretta A. Williams, Charles S. Cleeland, Patrick M. Dougherty. (2013) Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemotherapy and Pharmacology 71:6, 1531-1540
7
M. L. Orta, J. M. Calderon-Montano, I. Dominguez, N. Pastor, E. Burgos-Moron, M. Lopez-Lazaro, F. Cortes, S. Mateos, T. Helleday. (2013) 5-Aza-2'-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair. Nucleic Acids Research 41:11, 5827-5836
8
Teresa Caballero-Velázquez, Lucia López-Corral, Cristina Encinas, Cristina Castilla-Llorente, Rodrigo Martino, Laura Rosiñol, Antonia Sampol, Dolores Caballero, David Serrano, Inmaculada Heras, Jesús San Miguel, José A. Pérez-Simón. (2013) Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. British Journal of Haematologyn/a-n/a
9
S. Vincent Rajkumar. (2013) IV. Initial treatment of multiple myeloma. Hematological Oncology 31:S1, 33-37
10
Massimo Gentile, Anna Grazia Recchia, Carla Mazzone, Eugenio Lucia, Ernesto Vigna, Fortunato Morabito. (2013) Perspectives in the treatment of multiple myeloma. Expert Opinion on Biological Therapy1-22
11
A J Jakubowiak, D S Siegel, T Martin, M Wang, R Vij, S Lonial, S Trudel, V Kukreti, N Bahlis, M Alsina, A Chanan-Khan, F Buadi, F J Reu, G Somlo, J Zonder, K Song, A K Stewart, E Stadtmauer, B L Harrison, A F Wong, R Z Orlowski, S Jagannath. (2013) Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia
12
R. C. Turkington, C. Purcell, C. R. James, J. Millar, E. Napier, D. Law, R. Gallagher, M. Morris, R. H. Wilson, M. M. Eatock. (2013) A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma. Investigational New Drugs
13
G Srivastava, V Rana, M Q Lacy, F K Buadi, S R Hayman, A Dispenzieri, M A Gertz, D Dingli, S Zeldenrust, S Russell, A McCurdy, P Kapoor, R Kyle, S V Rajkumar, S Kumar. (2013) Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia
14
Yoshiaki Ogawa, Kenshi Suzuki, Akira Sakai, Shinsuke Iida, Michinori Ogura, Kensei Tobinai, Morio Matsumoto, Kosei Matsue, Yasuhito Terui, Kazuteru Ohashi, Masami Ishii, Harumi Y. Mukai, Kiyoshi Ando, Tomomitsu Hotta. (2013) Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma. Cancer Sciencen/a-n/a
15
Massimo Martino, Attilio Olivieri, Massimo Offidani, Ernesto Vigna, Tiziana Moscato, Roberta Fedele, Mauro Montanari, Giuseppe Console, Massimo Gentile, Giuseppe Messina, Giuseppe Irrera, Fortunato Morabito. (2013) Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opinion on Investigational Drugs1-16
16
A. Romano, A. Chiarenza, U. Consoli, C. Conticello, S. Forte, G. Uccello, C. Vetro, M. Cavalli, F. Coppolino, G. A. Palumbo, F. Di Raimondo. (2013) Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. Annals of Oncology 24:4, 1038-1044
17
Anna Dmoszyńska. (2013) Leczenie chorych na szpiczaka plazmocytowego w starszym wieku niebędących kandydatami do autologicznej transplantacji komórek krwiotwórczych (autoSCT). Acta Haematologica Polonica 44:2, 110-115
18
Alessandra Romano, Concetta Conticello, Francesco Di Raimondo. (2013) Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy 5:4, 327-352
19
Sebastian Böttcher, Michael Hallek, Matthias Ritgen, Michael Kneba. (2013) The Role of Minimal Residual Disease Measurements in the Therapy for CLL. Hematology/Oncology Clinics of North America 27:2, 267-288
20
Joseph R. Mikhael, David Dingli, Vivek Roy, Craig B. Reeder, Francis K. Buadi, Suzanne R. Hayman, Angela Dispenzieri, Rafael Fonseca, Taimur Sher, Robert A. Kyle, Yi Lin, Stephen J. Russell, Shaji Kumar, P. Leif Bergsagel, Steven R. Zeldenrust, Nelson Leung, Matthew T. Drake, Prashant Kapoor, Stephen M. Ansell, Thomas E. Witzig, John A. Lust, Robert J. Dalton, Morie A. Gertz, Keith Stewart, S. Vincent Rajkumar, Asher Chanan-Khan, Martha Q. Lacy. (2013) Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings 88:4, 360-376
21
Antonio Palumbo, Roberto Mina. (2013) Management of older adults with multiple myeloma. Blood Reviews
22
H R Stone, J R Morris. (2013) DNA damage emergency: cellular garbage disposal to the rescue?. Oncogene
23
Reiko Watanabe, Michihide Tokuhira, Masahiro Kizaki. (2013) Current approaches for the treatment of multiple myeloma. International Journal of Hematology
24
Badran Abu Zaid, Ali Abdul-Hai, Itamar Grotto, Lillian Dray, Igor B. Resnick, Panagiotis D. Tsirigotis, Simcha Samuel, Reuven Or, Michael Y. Shapira. (2013) Autologous transplantation in multiple myeloma with an augmented conditioning protocol. Leukemia & Lymphoma1-13
25
Benjamin M. Cherry, Neha Korde, Mary Kwok, Mark Roschewski, Ola Landgren. (2013) Evolving therapeutic paradigms for multiple myeloma: back to the future. Leukemia & Lymphoma 54:3, 451-463
26
Maria T. Petrucci, Pilar Giraldo, Paolo Corradini, Adriana Teixeira, Meletios A. Dimopoulos, Igor W. Blau, Johannes Drach, Ralf Angermund, Nathalie Allietta, Esther Broer, Vivien Mitchell, Joan Bladé. (2013) A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British Journal of Haematology 160:5, 649-659
27
Maria Teresa Petrucci, Anna Levi, Sara Bringhen, Simona Scotti, Fabiana Gentilini, Simone Russo, Agostina Siniscalchi, Alessandra Larocca, Sara Grammatico, Mario Boccadoro, Robin Foà, Antonio Palumbo. (2013) Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma. Cancer 119:5, 971-977
28
S. Vincent Rajkumar. (2013) Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. American Journal of Hematology 88:3, 225-235
29
L Nayak, H M Lazarus. (2013) Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?. Bone Marrow Transplantation 48:3, 338-345
30
H Avet-Loiseau, B G M Durie, M Cavo, M Attal, N Gutierrez, J Haessler, H Goldschmidt, R Hajek, J H Lee, O Sezer, B Barlogie, J Crowley, R Fonseca, N Testoni, F Ross, S V Rajkumar, P Sonneveld, J Lahuerta, P Moreau, G Morgan. (2013) Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 27:3, 711-717
31
P Falco, F Cavallo, A Larocca, D Rossi, T Guglielmelli, A Rocci, M Grasso, M L M Siez, L De Paoli, S Oliva, S Molica, R Mina, F Gay, G Benevolo, P Musto, P Omedè, R Freilone, S Bringhen, A M Carella, G Gaidano, M Boccadoro, A Palumbo. (2013) Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia 27:3, 695-701
32
Lauren A. Held, David Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, Cristina Gasparetto. (2013) A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma. Cancer Investigation 31:3, 172-176
33
Ali McBride, Patricia Y Ryan. (2013) Proteasome inhibitors in the treatment of multiple myeloma. Expert Review of Anticancer Therapy 13:3, 339-358
34
Sally Moore, Sangeeta Atwal, Sajitha Sachchithanantham, Matthew Streetly, Iftekhar Khan, Laura Percy, Santosh Narat, Shirley D'Sa, Neil Rabin, Rosalynd Johnston, Steve Schey, Kwee Yong. (2013) Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma. European Journal of Haematologyn/a-n/a
35
Marta Chesi, P. Leif Bergsagel. (2013) Molecular pathogenesis of multiple myeloma: basic and clinical updates. International Journal of Hematology
36
P. L. Bergsagel, M.-V. Mateos, N. C. Gutierrez, S. V. Rajkumar, J. F. San Miguel. (2013) Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 121:6, 884-892
37
Melhem Solh, Richard I Fisher, André de Vos, Steven H Bernstein, Dixie-Lee Esseltine, Rachel Neuwirth, Vicki A Morrison. (2013) Herpes Zoster Complicating Bortezomib Therapy of Relapsed/Refractory Indolent B-Cell and Mantle Cell Lymphoma: An Analysis of Two Phase II Trials. Leukemia & Lymphoma1-16
38
Giada Bianchi, Irene M. Ghobrial. (2013) Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. Leukemia & Lymphoma 54:2, 229-241
39
K. Suzuki. (2013) Current Therapeutic Strategy for Multiple Myeloma. Japanese Journal of Clinical Oncology 43:2, 116-124
40
Ajai Chari, Kevin Barley, Sundar Jagannath, Keren Osman. (2013) Safety and Efficacy of Triplet Regimens in Newly Diagnosed Light Chain Amyloidosis. Clinical Lymphoma Myeloma and Leukemia 13:1, 55-61
41
Darrell J. White, Nizar J. Bahlis, Deb C. Marcellus, Andrew Belch, A. Keith Stewart, Christine Chen, Michael J. Kovacs, David A. Macdonald, Donna E. Reece, Tony Reiman, Erica Harnett, Ralph M. Meyer, Judy-Anne W. Chapman, Stephen Couban. (2013) Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial. Clinical Lymphoma Myeloma and Leukemia 13:1, 19-24
42
F Magrangeas, H Avet-Loiseau, W Gouraud, L Lodé, O Decaux, P Godmer, L Garderet, L Voillat, T Facon, A M Stoppa, G Marit, C Hulin, P Casassus, M Tiab, E Voog, E Randriamalala, K C Anderson, P Moreau, N C Munshi, S Minvielle. (2013) Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27:2, 473-481
43
Philip L McCarthy, Kouros Owzar, Theresa Hahn. (2013) Autologous hematopoietic stem cell transplantation and maintenance therapy for multiple myeloma. International Journal of Hematologic Oncology 2:1, 71-83
44
P. Casassus. (2013) Traitement du myélome multiple. EMC - Hématologie 8:1, 1-16
45
Sung-Hoon Jung, Soo-Young Bae, Jae-Sook Ahn, Seung-Ji Kang, Deok-Hwan Yang, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Je-Jung Lee. (2013) Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens. International Journal of Hematology
46
M. In: Ferri's Clinical Advisor 2013. Elsevier, 2013:646-728.
47
Rakesh Popat, Lenushka Maharaj, Heather Oakervee, Jamie Cavenagh, Simon Joel. (2013) Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma. British Journal of Haematology 160:1, 111-114
48
Ho Sup Lee, Yang Soo Kim, Kihyun Kim, Jin Seok Kim, Hyo Jung Kim, Chang-Ki Min, Cheolwon Suh, Hyeon-Seok Eom, Sung-Soo Yoon, Jae Hoon Lee, Min Kyong Kim, Sung-Hyun Kim, Sung Hwa Bae, Yeung-Chul Mun, Deog Yeon Jo, Joo-Seop Chung, . (2013) Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation. Journal of Korean Medical Science 28:1, 80
49
Michael Poon, Liang Zeng, Liying Zhang, Janey Hsiao, Erin Wong, Henry Lam, Gillian Bedard, Edward Chow. (2013) Incidence of skeletal morbidity rates over time in patients with multiple myeloma-related bone disease as reported in randomized trials employing bone-modifying agents. Journal of Comparative Effectiveness Research 2:1, 69-76
50
Anna Dmoszyńska, Adam Walter-Croneck, Lidia Usnarska-Zubkiewicz, Beata Stella-Hołowiecka, Jan Walewski, Grzegorz Charliński, Wiesław Wiktor Jędrzejczak, Elżbieta Wiater, Ewa Lech-Marańda, Joanna Mańko, Dominik Dytfeld, Mieczysław Komarnicki, Krzysztof Jamroziak, Tadeusz Robak, Artur Jurczyszyn, Aleksander Skotnicki, Krzysztof Giannopoulos. (2013) Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2013. Acta Haematologica Polonica 44:1, 3-47
51
Jorge Félix, Filipa Aragão, João M Almeida, Frederico J Calado, Diana Ferreira, António B Parreira, Ricardo Rodrigues, João F Rijo. (2013) Time-dependent endpoints as predictors of overall survival in multiple myeloma. BMC Cancer 13:1, 122
52
Mi-Ra You, Hyun-Jong Lim, Hee-Jeong Lee, Hyung-Ho Kim, Woo-Ram Moon, Choon-Hae Chung, Chi-Young Park, Sang-Gon Park. (2013) Effect of Cyclophosphamide and Prednisone as a First-line Treatment for Non-transplant Candidates with Multiple Myeloma. Korean Journal of Medicine 84:5, 690
53
Jan Smetana, Kristina Berankova, Romana Zaoralova, Pavel Nemec, Henrieta Greslikova, Renata Kupska, Aneta Mikulasova, Jan Frohlich, Sabina Sevcikova, Lucie Zahradova, Marta Krejci, Viera Sandecka, Martina Almasi, Petra Kaisarova, Hana Melicharova, Zdenek Adam, Miroslav Penka, Jiri Jarkovsky, Arthur Jurczyszyn, Roman Hajek, Petr Kuglik. (2013) Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib. Clinical Lymphoma Myeloma and Leukemia
54
Antonio Palumbo, Chiara Cerrato. (2013) Diagnosis and therapy of multiple myeloma. The Korean Journal of Internal Medicine 28:3, 263
55
Maurizio Zangari, Evangelos Terpos, Fenghuang Zhan, Guido Tricot. (2012) Impact of bortezomib on bone health in myeloma: A review of current evidence. Cancer Treatment Reviews 38:8, 968-980
56
Wenrong Huang, Jian Li, Honghua Li, Wenying Kang, Jian Bo, Yu Zhao, Chunji Gao, Daobin Zhou, Li Yu. (2012) High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy. Leukemia & Lymphoma 53:12, 2507-2510
57
Charles Butler, Daynna J. Wolff, Yubin Kang, Robert K. Stuart, Luciano J. Costa. (2012) Association of age with fluorescence in situ hybridization abnormalities in multiple myeloma reveals higher rate of IGH translocations among older patients. Leukemia & Lymphoma 53:12, 2444-2448
58
L. Farnault, S. Chebrek, P. Souteyrand, G. Sebahoun, Regis Costello. (2012) Recurrent superior vena cava syndrome caused by IgD multiple myeloma. Annals of Hematology 91:12, 1977-1978
59
Hang Quach, Anna Kalff, Andrew Spencer. (2012) Lenalidomide in multiple myeloma: Current status and future potential. American Journal of Hematology 87:12, 1089-1095
60
Massimo Offidani, Laura Corvatta, Claudia Polloni, Riccardo Centurioni, Giuseppe Visani, Marino Brunori, Silvia Gentili, Massimo Catarini, Arduino Samori, Nicola Blasi, Francesco Alesiani, Patrizia Caraffa, Maurizio Burattini, Piero Galieni, Paolo Fraticelli, Mario Ferranti, Luciano Giuliodori, Pietro Leoni. (2012) Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry. Clinical Lymphoma Myeloma and Leukemia 12:6, 423-432
61
Michelle L. Mauermann, Martin S. Blumenreich, Angela Dispenzieri, Nathan P. Staff. (2012) A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment. Muscle & Nerve 46:6, 964-970
62
Kevin D Boyd, Charlotte Pawlyn, Gareth J Morgan, Faith E Davies. (2012) Understanding the molecular biology of myeloma and its therapeutic implications. Expert Review of Hematology 5:6, 603-617
63
Eric Sanchez, Mingjie Li, Jennifer Li, Cathy Wang, Haiming Chen, Susan Jones-Bolin, Kathryn Hunter, Bruce Ruggeri, James R. Berenson. (2012) CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leukemia Research 36:11, 1422-1427
64
Pádraig D’Arcy, Stig Linder. (2012) Proteasome deubiquitinases as novel targets for cancer therapy. The International Journal of Biochemistry & Cell Biology 44:11, 1729-1738
65
María-Victoria Mateos. (2012) How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events. Leukemia Research 36, S35-S43
66
Antonio Palumbo. (2012) Novel agents and the paradigm of continuous treatment in multiple myeloma. Leukemia Research 36, S1-S2
67
Antonio Palumbo, Ruben Niesvizky. (2012) Sustained disease control in transplant-ineligible patients: the role of continuous therapy. Leukemia Research 36, S19-S26
68
James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Stephen J. Noga, Donald S. Gravenor, Dipti Patel-Donnelly, Robert S. Siegel, Tarun Kewalramani, Edward J. Gorak, Youram Nassir, Regina A. Swift, Debra Mayo. (2012) Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. British Journal of Haematologyn/a-n/a
69
Bruno Paiva, María-Belén Vídriales, María-Ángeles Montalbán, José J. Pérez, Norma C. Gutiérrez, Laura Rosiñol, Joaquín Martínez-López, María-Victoria Mateos, Lourdes Cordón, Albert Oriol, María-José Terol, María-Asunción Echeveste, Raquel De Paz, Felipe De Arriba, Luis Palomera, Javier de la Rubia, Joaquín Díaz-Mediavilla, Anna Sureda, Ana Gorosquieta, Adrian Alegre, Alejandro Martin, Juan-José Lahuerta, Joan Bladé, Alberto Orfao, Jesús F. San Miguel. (2012) Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials. The American Journal of Pathology 181:5, 1870-1878
70
Beiqing Pan, Suzanne Lentzsch. (2012) The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacology & Therapeutics 136:1, 56-68
71
Claudio Cartoni, Gregorio Antonio Brunetti, Vincenzo Federico, Fabio Efficace, Sara Grammatico, Andrea Tendas, Laura Scaramucci, Luca Cupelli, Gianna Maria D’Elia, Andrea Truini, Pasquale Niscola, Maria Teresa Petrucci. (2012) Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. Supportive Care in Cancer 20:10, 2621-2626
72
Jiri Minarik, Tomas Pika, Jaroslav Bacovsky, Katerina Langova, Vlastimil Scudla. (2012) Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. British Journal of Haematology 159:1, 111-113
73
W. Michael Kuehl, P. Leif Bergsagel. (2012) Molecular pathogenesis of multiple myeloma and its premalignant precursor. Journal of Clinical Investigation 122:10, 3456-3463
74
Henry Dong, Hai-Su Yang, Sundar Jagannath, Christine F. Stephenson, Pauline Brenholz, Amitabha Mazumder, Ajai Chari. (2012) Risk Stratification of Plasma Cell Neoplasm: Insights From Plasma Cell–Specific Cytoplasmic Immunoglobulin Fluorescence in Situ Hybridization (cIg FISH) vs. Conventional FISH. Clinical Lymphoma Myeloma and Leukemia 12:5, 366-374
75
Sundar Jagannath, Ravi Vij, A. Keith Stewart, Suzanne Trudel, Andrzej J. Jakubowiak, Tony Reiman, George Somlo, Nizar Bahlis, Sagar Lonial, Lori A. Kunkel, Alvin Wong, Robert Z. Orlowski, David S. Siegel. (2012) An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 12:5, 310-318
76
Kenshi Suzuki. (2012) Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clinical and Experimental Nephrology 16:5, 659-671
77
Anastasia Markopoulou, Vasileios C. Kyttaris. (2012) Small Molecules in the treatment of systemic lupus erythematosus. Clinical Immunology
78
Alessandra Larocca, Federica Cavallo, Roberto Mina, Mario Boccadoro, Antonio Palumbo. (2012) Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. Future Oncology 8:10, 1223-1238
79
Ajay Nooka, Sagar Lonial. (2012) Sequential or combination therapy for multiple myeloma. Expert Review of Hematology 5:5, 533-545
80
Klaus Podar. (2012) Ask the Experts: Deriving new treatment strategies in multiple myeloma. International Journal of Hematologic Oncology 1:1, 21-26
81
Nabeel Chauhan, Bart Barlogie, Saad Z Usmani. (2012) Impediments to curing myeloma in 2012. International Journal of Hematologic Oncology 1:1, 29-34
82
Nicole Wilson, Minal Surati, Bruce F. Walker, Jonathan L. Kaufman, R. Donald Harvey. (2012) Bortezomib Administration With Severe Hyperbilirubinemia Caused by Hepatic Plasma Cell Infiltration: A Case Report. Clinical Lymphoma Myeloma and Leukemia
83
Hadass Pri-Chen, Ajai Chari. (2012) Erectile Dysfunction Associated with Bortezomib Treatment in a Patient with Multiple Myeloma and Amyloidosis. Clinical Lymphoma Myeloma and Leukemia
84
Chongmei Huang, Xiaoxia Hu, Libing Wang, Shuqing Lü, Hui Cheng, Xianmin Song, Jianmin Wang, Jianmin Yang. (2012) Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro. Cancer Chemotherapy and Pharmacology
85
Richard Haynes, Nelson Leung, Robert Kyle, Christopher G. Winearls. (2012) Myeloma Kidney: Improving Clinical Outcomes?. Advances in Chronic Kidney Disease 19:5, 342-351
86
Massimo Offidani, Claudia Polloni, Federica Cavallo, Anna Marina Liberati, Stelvio Ballanti, Stefano Pulini, Massimo Catarini, Francesco Alesiani, Laura Corvatta, Silvia Gentili, Patrizia Caraffa, Mario Boccadoro, Pietro Leoni, Antonio Palumbo. (2012) Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leukemia & Lymphoma 53:9, 1722-1727
87
Massimo Gentile, Anna Grazia Recchia, Carla Mazzone, Fortunato Morabito. (2012) Emerging biological insights and novel treatment strategies in multiple myeloma. Expert Opinion on Emerging Drugs 17:3, 407-438
88
Stephanie Stringer, Mark Cook, Paul Cockwell. (2012) Achieving an Early Myeloma Response in Patients With Kidney Impairment. Advances in Chronic Kidney Disease 19:5, 303-311
89
M.M. Álvarez-Cordovés, P.G. Mirpuri-Mirpuri, A. Pérez-Monje. (2012) Diagnóstico de mieloma múltiple en atención primaria. Sospecha ante una historia clínica adecuada. SEMERGEN - Medicina de Familia
90
P. Joy Ho, Ross D. Brown, Andrew Spencer, Melinda Jeffels, Daniel Daniher, John Gibson, Douglas E. Joshua. (2012) Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Leukemia & Lymphoma 53:9, 1728-1734
91
A Kalff, A Spencer. (2012) The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer Journal 2:9, e89
92
James R. Berenson. (2012) The future of treatment for multiple myeloma. Community Oncology 9:9, S47-S51
93
Sara Bringhen, Francesca Gay, Chiara Pautasso, Chiara Cerrato, Mario Boccadoro, Antonio Palumbo. (2012) Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism & Toxicology 8:9, 1209-1222
94
Shahrooz Eshaghian, James R. Berenson. (2012) Multiple myeloma. Current Opinion in Supportive and Palliative Care 6:3, 330-336
95
Joseph Pergolizzi, Jo LeQuang. Chemotherapy-Induced Peripheral Neuropathy. In: Chemotherapy Induced Neuropathic Pain. CRC Press, 2012:19-94.
96
P. Moreau, P. G. Richardson, M. Cavo, R. Z. Orlowski, J. F. San Miguel, A. Palumbo, J.-L. Harousseau. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120:5, 947-959
97
Yadan Wang, Lisha Ai, Guohui Cui, Bhuveshwarnath Gowrea, Mian Li, Yu Hu. (2012) Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma. Journal of Huazhong University of Science and Technology [Medical Sciences] 32:4, 495-500
98
Daryl Tan, Kiat H. Ong, Liang P. Koh, Siew S. Wong, Myat T. Khin, Lai H. Lee, Yeow T. Goh, Wee J. Chng. (2012) The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group. European Journal of Haematology 89:2, 136-144
99
Wolfram Pönisch, Marc Andrea, Ina Wagner, Doreen Hammerschmidt, Ute Kreibich, Andreas Schwarzer, Thomas Zehrfeld, Maik Schwarz, Cornelia Winkelmann, Sirak Petros, Anette Bachmann, Tom Lindner, Dietger Niederwieser. (2012) Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. Journal of Cancer Research and Clinical Oncology 138:8, 1405-1412
100
Jean El-Cheikh, Roberto Crocchiolo, Jean-Marie Boher, Sabine Fürst, Anne Marie Stoppa, Catherine Faucher, Luca Castagna, Angela Granata, Claire Oudin, Jean-Marc Schiano de Colella, Diane Coso, Reda Bouabdallah, Mohamad Mohty, Didier Blaise. (2012) Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?. Leukemia & Lymphoma 53:8, 1630-1632
101
Rashid Z Khan, Ashraf Badros. (2012) Role of carfilzomib in the treatment of multiple myeloma. Expert Review of Hematology 5:4, 361-372
102
J. A. Zonder, A. F. Mohrbacher, S. Singhal, F. van Rhee, W. I. Bensinger, H. Ding, J. Fry, D. E. H. Afar, A. K. Singhal. (2012) A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120:3, 552-559
103
Steffan T. Nawrocki, Patrick Griffin, Kevin R. Kelly, Jennifer S. Carew. (2012) MLN4924 : a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opinion on Investigational Drugs1-11
104
Tanya M. Wildes, Ravi Vij, Stephen H. Petersdorf, Bruno C. Medeiros, Arti Hurria. (2012) New treatment approaches for older adults with multiple myeloma. Journal of Geriatric Oncology 3:3, 279-290
105
Michel Delforge, Ravinder Dhawan, Don Robinson, Juliette Meunier, Antoine Regnault, Dixie-Lee Esseltine, Andrew Cakana, Helgi Velde, Paul G. Richardson, Jesús F. San Miguel. (2012) Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. European Journal of Haematology 89:1, 16-27
106
J.C. Titos-Arcos, J. León-Villar, F. de Arriba de la Fuente, M.J. Moreno Belmonte, M.D. Iranzo Fernández. (2012) Estudio observacional restrospectivo para evaluar la efectividad y seguridad de esquemas de tratamiento con bortezomib para el mieloma múltiple en nuestro hospital. Farmacia Hospitalaria 36:4, 275-281
107
Prashant Kapoor, Vijay Ramakrishnan, S. Vincent Rajkumar. (2012) Bortezomib Combination Therapy in Multiple Myeloma. Seminars in Hematology 49:3, 228-242
108
Christoph J. Heuck, John D. Shaughnessy. (2012) Proteasome Inhibitors: Introduction. Seminars in Hematology 49:3, 193-195
109
Andrzej Jakubowiak. (2012) Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives. Seminars in Hematology 49, S16-S32
110
Abhisek Swaika, Aneel Paulus, Kena C. Miller, Taimur Sher, Nikolaos G. Almyroudis, Donna Ball, Margaret Wood, Aisha Masood, Kelvin Lee, Asher A. Chanan-Khan. (2012) Acyclovir Prophylaxis Against Varicella Zoster Virus Reactivation in Multiple Myeloma Patients Treated With Bortezomib-Based Therapies: A Retrospective Analysis of 100 Patients. The Journal of Supportive Oncology 10:4, 155-159
111
J R Berenson, O Yellin, T Kazamel, J D Hilger, C-S Chen, A Cartmell, T Woliver, M Flam, E Bravin, Y Nassir, R Vescio, R A Swift. (2012) A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. Leukemia 26:7, 1675-1680
112
Jesús Feliu, Amaya Zabalza, Ricardo García-Muñoz, Eduardo Olavarría. (2012) Tiempos modernos: retorno al pasado, regreso al futuro. Medicina Clínica 139:4, 180-181
113
Dixie-Lee Esseltine, George Mulligan. (2012) An Historic Perspective of Proteasome Inhibition. Seminars in Hematology 49:3, 196-206
114
Gregory J. Kubicek, Rita S. Axelrod, Mitchell Machtay, Peter H. Ahn, Pramila R. Anne, Shannon Fogh, David Cognetti, Thomas J. Myers, Walter J. Curran, Adam P. Dicker. (2012) Phase I Trial Using the Proteasome Inhibitor Bortezomib and Concurrent Chemoradiotherapy for Head-and-Neck Malignancies. International Journal of Radiation Oncology*Biology*Physics 83:4, 1192-1197
115
Gabriella Parma, Rosanna Mancari, Gianluca Del Conte, Giovanni Scambia, Angiolo Gadducci, Dagmar Hess, Dionyssios Katsaros, Cristiana Sessa, Andrea Rinaldi, Francesco Bertoni, Andrea Vitali, Carlo Vittorio Catapano, Silvia Marsoni, Helgi van de Velde, Nicoletta Colombo. (2012) An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens. International Journal of Gynecological Cancer 22:5, 792-800
116
Tomoaki Tanaka, Tatsuya Nakatani, Tetsu Kamitani. (2012) Inhibition of NEDD8-conjugation pathway by novel molecules: Potential approaches to anticancer therapy. Molecular Oncology 6:3, 267-275
117
Caroline Rousseau, Ludovic Ferrer, Stéphane Supiot, Manuel Bardiès, François Davodeau, Alain Faivre-Chauvet, Pierre Baumgartner, John Wijdenes, Marie Lacombe, Jacques Barbet, Thierry Guillaume, Philippe Moreau, Jean Luc Harousseau, Françoise Kraeber-Bodéré, Michel Cherel. (2012) Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumor Biology 33:3, 679-688
118
Taiga Nishihori, Todd J. Alekshun, Kenneth Shain, Daniel M. Sullivan, Rachid Baz, Lia Perez, Joseph Pidala, Mohamed A. Kharfan-Dabaja, Jose L. Ochoa-Bayona, Hugo F. Fernandez, Danielle N. Yarde, Vasco Oliveira, William Fulp, Gang Han, Jongphil Kim, Dung-Tsa Chen, Jyoti Raychaudhuri, William Dalton, Claudio Anasetti, Melissa Alsina. (2012) Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. British Journal of Haematology 157:5, 553-563
119
Giovanni Barosi, Giampaolo Merlini, Atto Billio, Mario Boccadoro, Paolo Corradini, Monia Marchetti, Massimo Massaia, Patrizia Tosi, Antonio Palumbo, Michele Cavo, Sante Tura. (2012) SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Annals of Hematology 91:6, 875-888
120
Martina Guthoff, Barbara Schmid-Horch, Katja C. Weisel, Hans-Ulrich Häring, Alfred Königsrainer, Nils Heyne. (2012) Proteasome inhibition by bortezomib: Effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transplant Immunology 26:4, 171-175
121
Jennifer G Gaultney, William K Redekop, Pieter Sonneveld, Carin A Uyl-de Groot. (2012) Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value. Expert Review of Anticancer Therapy 12:6, 839-854
122
Shin Ogita, Patricia LoRusso, Jing Li. Oral Chemotherapeutic Agents. In: Encyclopedia of Drug Metabolism and Interactions. John Wiley & Sons, Inc., 2012.
123
Palumbo , Antonio , Hajek , Roman , Delforge , Michel , Kropff , Martin , Petrucci , Maria Teresa , Catalano , John , Gisslinger , Heinz , Wiktor-Jędrzejczak , Wiesław , Zodelava , Mamia , Weisel , Katja , Cascavilla , Nicola , Iosava , Genadi , Cavo , Michele , Kloczko , Janusz , Bladé , Joan , Beksac , Meral , Spicka , Ivan , Plesner , Torben , Radke , Joergen , Langer , Christian , Yehuda , Dina Ben , Corso , Alessandro , Herbein , Lindsay , Yu , Zhinuan , Mei , Jay , Jacques , Christian , Dimopoulos , Meletios A. , . (2012) Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. New England Journal of Medicine 366:19, 1759-1769
Free Full Text124
S. Kumar, I. Flinn, P. G. Richardson, P. Hari, N. Callander, S. J. Noga, A. K. Stewart, F. Turturro, R. Rifkin, J. Wolf, J. Estevam, G. Mulligan, H. Shi, I. J. Webb, S. V. Rajkumar. (2012) Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 119:19, 4375-4382
125
Miki Kiyota, Tsutomu Kobayashi, Shinichi Fuchida, Mio Yamamoto-Sugitani, Muneo Ohshiro, Yuji Shimura, Shinsuke Mizutani, Hisao Nagoshi, Nana Sasaki, Ryuko Nakayama, Yoshiaki Chinen, Natsumi Sakamoto, Hitoji Uchiyama, Yosuke Matsumoto, Shigeo Horiike, Chihiro Shimazaki, Junya Kuroda, Masafumi Taniwaki. (2012) Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. International Journal of Hematology 95:5, 516-526
126
Manish Sharma, Hassan Khan, Peter F. Thall, Robert Z. Orlowski, Roland L. Bassett, Nina Shah, Qaiser Bashir, Simrit Parmar, Michael Wang, Jatin J. Shah, Chitra M. Hosing, Uday R. Popat, Sergio A. Giralt, Richard E. Champlin, Muzaffar H. Qazilbash. (2012) A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118:9, 2507-2515
127
Paul G. Richardson, Jacob P. Laubach, Robert L. Schlossman, Irene M. Ghobrial, Katherine C. Redman, Mary Mckenney, Diane Warren, Kimberly Noonan, Laura Lunde, Deborah Doss, Kathleen Colson, Teru Hideshima, Constantine Mitsiades, Nikhil C. Munshi, Kenneth C. Anderson. (2012) The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. European Journal of Haematology 88:5, 446-449
128
Britta Lamottke, Martin Kaiser, Maren Mieth, Ulrike Heider, Zhenhai Gao, Zariana Nikolova, Michael R. Jensen, Jan Sterz, Ivana von Metzler, Orhan Sezer. (2012) The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. European Journal of Haematology 88:5, 406-415
129
Gerrard Teoh, Yuming Chen, Kihyun Kim, Alok Srivastava, Vasant R. Pai, Sung-Soo Yoon, Cheolwon Suh, Yeo-Kyeoung Kim. (2012) Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 12:2, 118-126
130
S. Kumar, R. Fonseca, R. P. Ketterling, A. Dispenzieri, M. Q. Lacy, M. A. Gertz, S. R. Hayman, F. K. Buadi, D. Dingli, R. A. Knudson, A. Greenberg, S. J. Russell, S. R. Zeldenrust, J. A. Lust, R. A. Kyle, L. Bergsagel, S. V. Rajkumar. (2012) Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 119:9, 2100-2105
131
James J. Driscoll, Jason Burris, Christina M. Annunziata. (2012) Targeting the Proteasome With Bortezomib in Multiple Myeloma. American Journal of Therapeutics 19:2, 133-144
132
C.-F. Lee, F.Z. Eldeen, K.-M. Chan, T.-H. Wu, R.-S. Soong, T.-J. Wu, H.-S. Chou, W.-C. Lee. (2012) Bortezomib Is Effective to Treat Acute Humoral Rejection After Liver Transplantation. Transplantation Proceedings 44:2, 529-531
133
Kenneth C. Anderson. (2012) Bench-to-bedside translation of targeted therapies in multiple myeloma. Community Oncology 9:3, 87-93
134
Lisa Dalla Via, Chiara Nardon, Dolores Fregona. (2012) Targeting the ubiquitin–proteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Future Medicinal Chemistry 4:4, 525-543
135
Anuj Mahindra, Jacob Laubach, Noopur Raje, Nikhil Munshi, Paul G. Richardson, Kenneth Anderson. (2012) Latest advances and current challenges in the treatment of multiple myeloma. Nature Reviews Clinical Oncology 9:3, 135-143
136
Lale Ozcan, Ira Tabas. (2012) Role of Endoplasmic Reticulum Stress in Metabolic Disease and Other Disorders. Annual Review of Medicine 63:1, 317-328
137
Antonio Palumbo, Jon Bladé, Mario Boccadoro, Carmela Palladino, Faith Davies, Meletios Dimopoulos, Anna Dmoszynska, Hermann Einsele, Philippe Moreau, Orhan Sezer, Andrew Spencer, Pieter Sonneveld, Jesus San Miguel. (2012) How to Manage Neutropenia in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 12:1, 5-11
138
George P. Kim, Michelle R. Mahoney, Daniel Szydlo, Tony S. K. Mok, Robert Marshke, Kyle Holen, Joel Picus, Michael Boyer, Henry C. Pitot, Joseph Rubin, Philip A. Philip, Anna Nowak, John J. Wright, Charles Erlichman. (2012) An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Investigational New Drugs 30:1, 387-394
139
Meaghan L. Khan, Craig B. Reeder, Shaji K. Kumar, Marthy Q. Lacy, Donna E. Reece, Angela Dispenzieri, Morie A. Gertz, Phillip Greipp, Suzanne Hayman, Steven Zeldenhurst, David Dingli, John Lust, Stephen Russell, Kristina M. Laumann, Joseph R. Mikhael, P. Leif Bergsagel, Rafael Fonseca, S. Vincent Rajkumar, A. Keith Stewart. (2012) A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. British Journal of Haematology 156:3, 326-333
140
I. Charlot-Lambrecht, J.-H. Salmon, L. Gagneux-Lemoussu, P. Brochot, J.-P. Eschard. (2012) Mieloma múltiple. EMC - Aparato Locomotor 45:1, 1-13
141
Allan Jiang, Donna Reece, Hong Chang. (2012) Genomic stratification of multiple myeloma treated with novel agents. Leukemia & Lymphoma 53:2, 202-207
142
K D Boyd, F M Ross, L Chiecchio, G P Dagrada, Z J Konn, W J Tapper, B A Walker, C P Wardell, W M Gregory, A J Szubert, S E Bell, J A Child, G H Jackson, F E Davies, G J Morgan. (2012) A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 26:2, 349-355
143
M. Lacombe, L. Ferrer, S. Supiot, M. Bardiès, F. Davodeau, A. Faivre-Chauvet, P. Baumgartner, J. Wijdenes, J. Barbet, T. Guillaume, P. Moreau, J.-L. Harousseau, F. Kraeber-Bodéré, M. Cherel, C. Rousseau. (2012) Étude clinique de phase I avec bénéfice individuel direct de radioimmunothérapie du myélome multiple utilisant l’anticorps anti-CD138 marqué à l’iode 131 (131I-B-B4). Médecine Nucléaire 36:2, 83-93
144
Cristina João, Alfredo Figueiredo, Helena Figueira Martins. (2012) Advantageous use of lenalidomide in multiple myeloma. Current Opinion in Oncology 24, S13-S20
145
K. Neben, H. M. Lokhorst, A. Jauch, U. Bertsch, T. Hielscher, B. van der Holt, H. Salwender, I. W. Blau, K. Weisel, M. Pfreundschuh, C. Scheid, U. Duhrsen, W. Lindemann, I. G. H. Schmidt-Wolf, N. Peter, C. Teschendorf, H. Martin, M. Haenel, H. G. Derigs, M. S. Raab, A. D. Ho, H. van de Velde, D. Hose, P. Sonneveld, H. Goldschmidt. (2012) Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119:4, 940-948
146
Andrea K. Ng, Kenneth C. Anderson, Anuj Mahindra. Multiple Myeloma and Other Plasma Cell Neoplasms. In: Clinical Radiation Oncology. Elsevier, 2012:1573-1581.
147
Boris Cvek. Proteasome Inhibitors. Elsevier, 2012:161-226.
148
Hakan Kaya, Benjamin Peressini, Irfan Jawed, Danko Martincic, Ameer L. Elaimy, Wayne T. Lamoreaux, Robert K. Fairbanks, Kevin A. Weeks, Christopher M. Lee. (2012) Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. International Journal of Hematology 95:1, 64-70
149
Hematology. In: Conn's Current Therapy 2012. Elsevier, 2012:767-871.
150
S. Vincent Rajkumar. (2012) Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. American Journal of Hematology 87:1, 78-88
151
Tamara Miner Haygood, Edith M. Marom, Donna M. Weber. Myeloma and Leukemia. In: Oncologic Imaging: A Multidisciplinary Approach. Elsevier, 2012:509-529.
152
Chor Chim, Albert Kwok Lie, Eric Yuk Chan, Herman Sung Liu, Ching Lau, Sze Yip, Joycelyn Sim, Thomas Wan, Edmond Ma, Raymond Liang, Eric Tse, Yok-Lam Kwong, . (2012) Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. Journal of Hematology & Oncology 5:1, 28
153
Cun Wang, Dongmei Gao, Kun Guo, Xiaonan Kang, Kai Jiang, Chun Sun, Yan Li, Lu Sun, Hong Shu, Guangzhi Jin, Haiyan Sun, Weizhong Wu, Yinkun Liu. (2012) Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. BMC Cancer 12:1, 166
154
Ashley Jeter, Yubin Kang. (2012) Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy. Experimental Hematology & Oncology 1:1, 20
155
S. Vincent Rajkumar. Plasma Cell Disorders. In: Goldman's Cecil Medicine. Elsevier, 2012:1233-1243.
156
Anna Dmoszyńska, Adam Walter-Croneck, Joanna Mańko, Lidia Usnarska-Zubkiewicz, Beata Stella-Hołowiecka, Jan Walewski, Grzegorz Charliński, Wiesław Wiktor Jędrzejczak, Elżbieta Wiater, Ewa Lech-Marańda, Dominik Dytfeld, Mieczysław Komarnicki, Krzysztof Giannopoulos, Krzysztof Jamroziak, Tadeusz Robak, Artur Jurczyszyn, Aleksander Skotnicki. (2012) Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego na rok 2012. Acta Haematologica Polonica 43:1, 7-47
157
Rui Bergantim, Fernanda Trigo, José E Guimarães. (2012) Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma. Experimental Hematology & Oncology 1:1, 35
158
R. Fonseca. (2011) Innovation in myeloma treatments PARP excellence!. Blood 118:24, 6234-6235
159
Ticiana B. Leal, Scot C. Remick, Chris H. Takimoto, Ramesh K. Ramanathan, Angela Davies, Merrill J. Egorin, Anne Hamilton, Patricia A. LoRusso, Stephen Shibata, Heinz-Josef Lenz, James Mier, John Sarantopoulos, Sridhar Mani, John J. Wright, S. Percy Ivy, Rachel Neuwirth, Lisa Moltke, Karthik Venkatakrishnan, Daniel Mulkerin. (2011) Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemotherapy and Pharmacology 68:6, 1439-1447
160
Evangelos Eleftherakis-Papapiakovou, Esftathios Kastritis, Maria Roussou, Maria Gkotzamanidou, Irini Grapsa, Erasmia Psimenou, Nikitas Nikitas, Evangelos Terpos, Meletios A. Dimopoulos. (2011) Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. Leukemia & Lymphoma 52:12, 2299-2303
161
Marta Krejci, Evzen Gregora, Jan Straub, Jiri Minarik, Vlastimil Scudla, Zdenek Adam, Andrea Krivanova, Ludek Pour, Lenka Zahradova, Tomas Buchler, Jiri Mayer, Roman Hajek. (2011) Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma. Annals of Hematology 90:12, 1441-1447
162
Jesús Martín Sánchez. (2011) Continued treatment with lenalidomide in multiple myeloma. Advances in Therapy 28:S8, 1-13
163
K. C. Anderson. (2011) New Insights into Therapeutic Targets in Myeloma. Hematology 2011:1, 184-190
164
M. Chesi, P. L. Bergsagel. (2011) Many Multiple Myelomas: Making More of the Molecular Mayhem. Hematology 2011:1, 344-353
165
Nicholas A. Barber, Apar Kishor Ganti. (2011) Pulmonary toxicities from targeted therapies: a review. Targeted Oncology 6:4, 235-243
166
Susanna J. Jacobus, Shaji Kumar, Hajime Uno, Scott A. Van Wier, Greg J. Ahmann, Kimberly J. Henderson, Natalie S. Callander, Michael E. Williams, David S. Siegel, Philip R. Greipp, S. Vincent Rajkumar, Rafael Fonseca. (2011) Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. British Journal of Haematology 155:3, 340-348
167
Michel Delforge. (2011) Bortezomib for previously untreated multiple myeloma. Expert Opinion on Pharmacotherapy 12:16, 2553-2564
168
Helen Marr, Gail L Jones, Graham H Jackson, Wendy Osborne. (2011) Diagnosis and management of haematological malignancies in older people. Reviews in Clinical Gerontology 21:04, 297-311
169
Éric Moumas, William Hanf, Estelle Desport, Julie Abraham, Sébastien Delbès, Céline Debiais, Laurence Lacotte-Thierry, Guy Touchard, Arnaud Jaccard, Jean-Paul Fermand, Frank Bridoux. (2011) Actualités dans le traitement du myélome avec insuffisance rénale. Néphrologie & Thérapeutique 7:6, 457-466
170
A. Palumbo, S. Bringhen, H. Ludwig, M. A. Dimopoulos, J. Blade, M. V. Mateos, L. Rosinol, M. Boccadoro, M. Cavo, H. Lokhorst, S. Zweegman, E. Terpos, F. Davies, C. Driessen, P. Gimsing, M. Gramatzki, R. Hajek, H. E. Johnsen, F. Leal Da Costa, O. Sezer, A. Spencer, M. Beksac, G. Morgan, H. Einsele, J. F. San Miguel, P. Sonneveld. (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118:17, 4519-4529
171
M.-V. Mateos, N. C. Gutierrez, M.-L. Martin-Ramos, B. Paiva, M.-A. Montalban, A. Oriol, J. Martinez-Lopez, A.-I. Teruel, E. Bengoechea, A. Martin, J. Diaz-Mediavilla, F. de Arriba, L. Palomera, J.-M. Hernandez, A. Sureda, J. Bargay, F.-J. Penalver, J.-M. Ribera, M.-L. Martin-Mateos, M. Fernandez, R. Garcia-Sanz, M.-B. Vidriales, J. Blade, J.-J. Lahuerta, J. F. San Miguel. (2011) Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood 118:17, 4547-4553
172
S. K. Kumar, H. Uno, S. J. Jacobus, S. A. V. Wier, G. J. Ahmann, K. J. Henderson, N. S. Callander, J. L. Haug, D. S. Siegel, P. R. Greipp, R. Fonseca, S. V. Rajkumar. (2011) Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 118:16, 4359-4362
173
Magdalini Migkou, Efstathios Kastritis, Maria Roussou, Maria Gkotzamanidou, Maria Gavriatopoulou, Nikitas Nikitas, Despina Mparmparoussi, Charis Matsouka, Dimitra Gika, Evangelos Terpos, Meletios A. Dimopoulos. (2011) Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. European Journal of Haematology 87:4, 323-329
174
Hadi Manji. (2011) Toxic neuropathy. Current Opinion in Neurology 24:5, 484-490
175
Valerie Reed, Jatin Shah, L. Jeffery Medeiros, Chul S. Ha, Ali Mazloom, Donna M. Weber, Isidora Y. Arzu, Robert Z. Orlowski, Sheeba K. Thomas, Ferial Shihadeh, Raymond Alexanian, Bouthaina S. Dabaja. (2011) Solitary plasmacytomas. Cancer 117:19, 4468-4474
176
Prashant Kapoor, S. Vincent Rajkumar. (2011) Update on risk stratification and treatment of newly diagnosed multiple myeloma. International Journal of Hematology 94:4, 310-320
177
Sarah K. Johnson, Christoph J. Heuck, Anthony P. Albino, Pingping Qu, Qing Zhang, Bart Barlogie, John D. Shaughnessy. (2011) The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. International Journal of Hematology 94:4, 321-333
178
J. D. Shaughnessy, P. Qu, S. Usmani, C. J. Heuck, Q. Zhang, Y. Zhou, E. Tian, I. Hanamura, F. van Rhee, E. Anaissie, J. Epstein, B. Nair, O. Stephens, R. Williams, S. Waheed, Y. Alsayed, J. Crowley, B. Barlogie. (2011) Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 118:13, 3512-3524
179
Claudia Rossig, Heribert Juergens, Wolfgang E. Berdel. (2011) New Targets and Targeted Drugs for the Treatment of Cancer: An Outlook to Pediatric Oncology. Pediatric Hematology-Oncology 28:7, 539-555
180
S. V. Rajkumar, G. Gahrton, P. L. Bergsagel. (2011) Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 118:12, 3205-3211
181
K. Bauer, M. Rancea, B. Schmidtke, S. Kluge, I. Monsef, K. Hubel, A. Engert, N. Skoetz. (2011) Thirteenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Multiple Myeloma. JNCI Journal of the National Cancer Institute 103:17, E1-E19
182
Emanuel Haasbach, Eva-Katharina Pauli, Robert Spranger, David Mitzner, Ulrich Schubert, Ralf Kircheis, Oliver Planz. (2011) Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses. Antiviral Research 91:3, 304-313
183
JOHN QUINN, FRAN PERCIVAL, MARTIN AUGER, SUPRATIK BASU, PATRICK CHU, MAADH ALDOURI, ADRIAN LAMBOURNE, SABINE GAUGRIS, KWEE YONG. (2011) Relapsed multiple myeloma in the UK prior to the introduction of novel agents - a response to Koleva et al. (2010). European Journal of Cancer Care 20:5, 697-699
184
Meletios A. Dimopoulos, Evangelos Terpos. (2011) Advances in the treatment of multiple myeloma. European Journal of Cancer 47, S306-S308
185
Sally Doss, Nicola Hay, Frances Sutcliffe. (2011) NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma. The Lancet Oncology 12:9, 837-838
186
Jordi Bruna, Albert Alé, Roser Velasco, Jessica Jaramillo, Xavier Navarro, Esther Udina. (2011) Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. Journal of the Peripheral Nervous System 16:3, 199-212
187
Paul G. Richardson, Sagar Lonial, Andrzej J. Jakubowiak, Jean-Luc Harousseau, Kenneth C. Anderson. (2011) Monoclonal antibodies in the treatment of multiple myeloma. British Journal of Haematology 154:6, 745-754
188
Ivan Spicka, MV Mateos, K Redman, MA Dimopoulos, PG Richardson. (2011) An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. Immunotherapy 3:9, 1033-1040
189
Rebecca Silbermann, G. David Roodman. (2011) Bone effects of cancer therapies. Current Opinion in Supportive and Palliative Care 5:3, 251-257
190
Beth M. Faiman, Patricia Mangan, Jacy Spong, Joseph D. Tariman. (2011) Renal Complications in Multiple Myeloma and Related Disorders. Clinical Journal of Oncology Nursing 15:0, 66-76
191
Shaji K. Kumar, Martha Q. Lacy, Suzanne R. Hayman, Keith Stewart, Francis K. Buadi, Jacob Allred, Kristina Laumann, Philip R. Greipp, John A. Lust, Morie A. Gertz, Steven R. Zeldenrust, P. Leif Bergsagel, Craig B. Reeder, Thomas E. Witzig, Rafael Fonseca, Stephen J. Russell, Joseph R. Mikhael, David Dingli, S. Vincent Rajkumar, Angela Dispenzieri. (2011) Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology 86:8, 640-645
192
Fabio P.S. Santos, Hagop Kantarjian, David McConkey, Susan O'Brien, Stefan Faderl, Gautam Borthakur, Alessandra Ferrajoli, John Wright, Jorge Cortes. (2011) Pilot Study of Bortezomib for Patients With Imatinib-Refractory Chronic Myeloid Leukemia in Chronic or Accelerated Phase. Clinical Lymphoma Myeloma and Leukemia 11:4, 355-360
193
Bertrand Coiffier, Evgenii A Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, Michael Crump, Ofer Shpilberg, Dixie-Lee Esseltine, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi van de Velde, Yusri A Elsayed, Pier Luigi Zinzani. (2011) Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology 12:8, 773-784
194
Javier de la Rubia, Mónica Roig. (2011) Bortezomib for previously untreated multiple myeloma. Expert Review of Hematology 4:4, 381-398
195
D. E. Reece, U. Hegenbart, V. Sanchorawala, G. Merlini, G. Palladini, J. Blade, J.-P. Fermand, H. Hassoun, L. Heffner, R. A. Vescio, K. Liu, C. Enny, D.-L. Esseltine, H. van de Velde, A. Cakana, R. L. Comenzo. (2011) Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 118:4, 865-873
196
J. Martinez-Lopez, J. Blade, M.-V. Mateos, C. Grande, A. Alegre, J. Garcia-Larana, A. Sureda, J. de la Rubia, E. Conde, R. Martinez, F. de Arriba, M. C. Viguria, J. Besalduch, R. Cabrera, J. D. Gonzalez-San Miguel, J. L. Guzman-Zamudio, M. C. Gomez del Castillo, J. M. Moraleda, J. C. Garcia-Ruiz, J. San Miguel, J. J. Lahuerta, . (2011) Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118:3, 529-534
197
A. M. Ruschak, M. Slassi, L. E. Kay, A. D. Schimmer. (2011) Novel Proteasome Inhibitors to Overcome Bortezomib Resistance. JNCI Journal of the National Cancer Institute 103:13, 1007-1017
198
Jennifer M. Bird, Roger G. Owen, Shirley D’Sa, John A. Snowden, Guy Pratt, John Ashcroft, Kwee Yong, Gordon Cook, Sylvia Feyler, Faith Davies, Gareth Morgan, Jamie Cavenagh, Eric Low, Judith Behrens, . (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology 154:1, 32-75
199
Stephanie A. Gregory, Steve Abella, Tim Moore. (2011) Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies. Community Oncology 8:7, 311-325
200
Dominik Dytfeld, Kent A. Griffith, Judah Friedman, Daniel Lebovic, Colleen Harvey, Mark S. Kaminski, Andrzej J. Jakubowiak. (2011) Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial. Leukemia & Lymphoma 52:7, 1271-1280
201
Antonio Palumbo, Maria-Victoria Mateos, Sara Bringhen, Jesús F. San Miguel. (2011) Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?. Blood Reviews 25:4, 181-191
202
Taimur Sher, Sikander Ailawadhi, Kena C. Miller, Debbie Manfredi, Margaret Wood, Wei Tan, Gregory Wilding, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri, Fredrick Hong, Raman Sood, Saif Soniwala, William Lawrence, Saad Jamshed, Aisha Masood, Daniel Iancu, Kelvin Lee, Asher Chanan-Khan. (2011) A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British Journal of Haematology 154:1, 104-110
203
P Moreau, M Attal, J L Harousseau. (2011) New developments in conditioning regimens before auto-SCT in multiple myeloma. Bone Marrow Transplantation 46:7, 911-915
204
Larry D. Anderson, Danielle R. Cook, Tori N. Yamamoto, Carolina Berger, David G. Maloney, Stanley R. Riddell. (2011) Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunology, Immunotherapy 60:7, 985-997
205
Sumit Madan, Shaji Kumar. (2011) Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. Therapy 8:4, 415-429
206
M. Cavo, S. V. Rajkumar, A. Palumbo, P. Moreau, R. Orlowski, J. Blade, O. Sezer, H. Ludwig, M. A. Dimopoulos, M. Attal, P. Sonneveld, M. Boccadoro, K. C. Anderson, P. G. Richardson, W. Bensinger, H. E. Johnsen, N. Kroeger, G. Gahrton, P. L. Bergsagel, D. H. Vesole, H. Einsele, S. Jagannath, R. Niesvizky, B. G. M. Durie, J. San Miguel, S. Lonial, . (2011) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 117:23, 6063-6073
207
Stefan Schmitt, H. Goldschmidt, B. Storch-Hagenlocher, M. Pham, G. Fingerle-Rowson, A. D. Ho, K. Neben. (2011) Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma. International Journal of Hematology 93:6, 791-794
208
Niels W.C.J. van de Donk, Henk M. Lokhorst, Meletios Dimopoulos, Michele Cavo, Gareth Morgan, Hermann Einsele, Martin Kropff, Steve Schey, Hervé Avet-Loiseau, Heinz Ludwig, Hartmut Goldschmidt, Pieter Sonneveld, Hans E. Johnsen, Joan Bladé, Jesús F. San-Miguel, Antonio Palumbo. (2011) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews 37:4, 266-283
209
Maurizio Zangari, Monette Aujay, Fenghuang Zhan, Kristina L. Hetherington, Tamara Berno, Ravi Vij, Sundar Jagannath, David Siegel, A. Keith Stewart, Luhua Wang, Robert Z. Orlowski, Andrew Belch, Andrzej Jakubowiak, George Somlo, Suzanne Trudel, Nizar Bahlis, Sagar Lonial, Seema Singhal, Vishal Kukreti, Guido Tricot. (2011) Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. European Journal of Haematology 86:6, 484-487
210
Stephen R. Byrn, Patrick A. Tishmack, Mark J. Milton, Helgi Velde. (2011) Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile. AAPS PharmSciTech 12:2, 461-467
211
M. Victoria Mateos, Jesús San-Miguel. (2011) Treatment of Newly Diagnosed Myeloma in Patients not Eligible for Transplantation. Current Hematologic Malignancy Reports 6:2, 113-119
212
S. Manier, X. Leleu. (2011) Myélome multiple : diagnostic clinique et perspective de traitement. Recommandations de l’International Myeloma Working Group (IMWG). Immuno-analyse & Biologie Spécialisée 26:3, 125-136
213
Hang Quach, H Miles Prince, Andrew Spencer. (2011) Managing multiple myeloma in the elderly: are we making progress?. Expert Review of Hematology 4:3, 301-315
214
Sascha A. Tuchman, Sagar Lonial. (2011) High-Risk Multiple Myeloma: Does it Still Exist?. Clinical Lymphoma Myeloma and Leukemia 11, S70-S76
215
Ulrike Klein, Anna Jauch, Thomas Hielscher, Jens Hillengass, Marc S. Raab, Anja Seckinger, Dirk Hose, Anthony D. Ho, Hartmut Goldschmidt, Kai Neben. (2011) Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer 117:10, 2136-2144
216
S. V. Rajkumar, J.-L. Harousseau, B. Durie, K. C. Anderson, M. Dimopoulos, R. Kyle, J. Blade, P. Richardson, R. Orlowski, D. Siegel, S. Jagannath, T. Facon, H. Avet-Loiseau, S. Lonial, A. Palumbo, J. Zonder, H. Ludwig, D. Vesole, O. Sezer, N. C. Munshi, J. San Miguel, . (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117:18, 4691-4695
217
Michihide Tokuhira, Reiko Watanabe, Tomoe Nemoto, Kyoko Hanzawa, Morihiko Sagawa, Takeshi Tomikawa, Shigehisa Mori, Masahiro Kizaki. (2011) Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma. Leukemia Research 35:5, 591-597
218
María-Victoria Mateos. (2011) Subcutaneous bortezomib: a step towards optimised drug use. The Lancet Oncology 12:5, 410-411
219
Giulia Benevolo, Alessandra Larocca, Massimo Gentile, Patrizia Pregno, Francesca Gay, Barbara Botto, Chiara Frairia, Andrea Evangelista, Fortunato Morabito, Mario Boccadoro, Umberto Vitolo, Antonio Palumbo. (2011) The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. Cancer 117:9, 1884-1890
220
Michel Delforge, Evangelos Terpos, Paul G. Richardson, Ofer Shpilberg, Nuriet K. Khuageva, Rudolf Schlag, Meletios A. Dimopoulos, Martin Kropff, Ivan Spicka, Maria T. Petrucci, Olga S. Samoilova, Maria-Victoria Mateos, Hila Magen-Nativ, Hartmut Goldschmidt, Dixie-Lee Esseltine, Deborah S. Ricci, Kevin Liu, William Deraedt, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel. (2011) Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. European Journal of Haematology 86:5, 372-384
221
Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Maria Grishunina, Grigoriy Rekhtman, Zvenyslava Masliak, Tadeusz Robak, Anna Shubina, Bertrand Arnulf, Martin Kropff, James Cavet, Dixie-Lee Esseltine, Huaibao Feng, Suzette Girgis, Helgi van de Velde, William Deraedt, Jean-Luc Harousseau. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology 12:5, 431-440
222
S. Vincent Rajkumar. (2011) Treatment of multiple myeloma. Nature Reviews Clinical Oncology 8:8, 479-491
223
Shaji Kumar, S. Vincent Rajkumar. Multiple Myeloma: Molecular Biology, Diagnosis and Treatment. In: Advances in Malignant Hematology. Wiley-Blackwell, 2011:315-341.
224
Bart Barlogie, Vanessa Bolejack, Michael Schell, John Crowley. (2011) Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Annals of Hematology 90:4, 423-428
225
Christopher Parrish, Julian Cromack, Sylvia Feyler, John Ashcroft, Roger Owen, Gordon Cook. (2011) Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years. British Journal of Haematology 153:2, 273-275
226
R. Schots. (2011) Recent advances in myeloma treatment. Transfusion and Apheresis Science 44:2, 223-229
227
P Kapoor, S V Rajkumar, A Dispenzieri, M A Gertz, M Q Lacy, D Dingli, J R Mikhael, V Roy, R A Kyle, P R Greipp, S Kumar, S J Mandrekar. (2011) Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 25:4, 689-696
228
Ibrahiem Saeed Abdul-Rahman. (2011) Renal Disease in Hematological Malignancies. Hong Kong Journal of Nephrology 13:1, 5-18
229
Simone Cenci, Eelco van Anken, Roberto Sitia. (2011) Proteostenosis and plasma cell pathophysiology. Current Opinion in Cell Biology 23:2, 216-222
230
Paul Richardson, Rudolf Schlag, Nuriet Khuageva, Meletios Dimopoulos, Ofer Shpilberg, Martin Kropff, Marie-Christiane Vekemans, Maria Teresa Petrucci, Viktor Rossiev, Jian Hou, Tadeusz Robak, Maria-Victoria Mateos, Kenneth Anderson, Dixie-Lee Esseltine, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel. (2011) Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agent. British Journal of Haematology 153:2, 212-221
231
Maurizio Zangari, Louis Fink, Fenghuang Zhan, Guido Tricot. (2011) Low Venous Thromboembolic Risk With Bortezomib in Multiple Myeloma and Potential Protective Effect With Thalidomide/Lenalidomide-based Therapy: Review of Data From Phase 3 Trials and Studies of Novel Combination Regimens. Clinical Lymphoma Myeloma and Leukemia 11:2, 228-236
232
Noopur Raje. (2011) Evolving therapies for multiple myeloma. Community Oncology 8:4, 181-182
233
Palumbo , Antonio , Anderson , Kenneth , . (2011) Multiple Myeloma. New England Journal of Medicine 364:11, 1046-1060
Full Text234
F. Gay, A. Larocca, P. Wijermans, F. Cavallo, D. Rossi, R. Schaafsma, M. Genuardi, A. Romano, A. M. Liberati, A. Siniscalchi, M. T. Petrucci, C. Nozzoli, F. Patriarca, M. Offidani, R. Ria, P. Omede, B. Bruno, R. Passera, P. Musto, M. Boccadoro, P. Sonneveld, A. Palumbo. (2011) Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117:11, 3025-3031
235
Nilanjan Ghosh, Xiaobu Ye, Anna Ferguson, Carol Ann Huff, Ivan Borrello. (2011) Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. British Journal of Haematology 152:5, 593-599
236
Eric Sanchez, Jing Shen, Jeffrey Steinberg, Mingjie Li, Cathy Wang, Benjamin Bonavida, Haiming Chen, Zhi-Wei Li, James R. Berenson. (2011) The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leukemia Research 35:3, 373-379
237
Ana G Alzaga Fernandez, Romina Shirka, Barry Skarf, Brian Silver, Selma J Matloob, Michael D Ober, Patrick Luetmer, Caterina Giannini. (2011) Bilateral Simultaneous Central Retinal Vein Occlusions in an Otherwise Healthy Adult. Journal of Neuro-Ophthalmology 31:1, 78-82
238
Francesca Gay, Antonio Palumbo. (2011) Management of older patients with multiple myeloma. Blood Reviews 25:2, 65-73
239
Jacob Laubach, Paul Richardson, Kenneth Anderson. (2011) Multiple Myeloma. Annual Review of Medicine 62:1, 249-264
240
H. Nahi, T. Sutlu, M. Jansson, E. Alici, G. Gahrton. (2011) Clinical impact of chromosomal aberrations in multiple myeloma. Journal of Internal Medicine 269:2, 137-147
241
Gregory Connolly. (2011) The impact of bortezomib on the risk of thrombosis in multiple myeloma. Leukemia Research 35:2, 145-146
242
M C Minnema, S van Dorp, N W C J van de Donk, F Schouten, M J Kersten, J L L M Coenen, H Schouten, S Zweegman, R Schaafsma, H M Lokhorst. (2011) Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience. Bone Marrow Transplantation 46:2, 244-249
243
Paul G. Richardson, Constantine S. Mitsiades, Jacob P. Laubach, Sagar Lonial, Asher A. Chanan-Khan, Kenneth C. Anderson. (2011) Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. British Journal of Haematology 152:4, 367-379
244
Lionel Karlin, Jean Soulier, Olivia Chandesris, Sylvain Choquet, Karim Belhadj, Margaret Macro, Didier Bouscary, Raphael Porcher, David Ghez, Marion Malphettes, Bouchra Asli, Jean Claude Brouet, Jean Christophe Bories, Olivier Hermine, Jean Paul Fermand, Bertrand Arnulf. (2011) Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leukemia & Lymphoma 52:2, 238-246
245
X. Armoiry, F. Fagnani, L. Benboubker, T. Facon, J. P. Fermand, C. Hulin, P. Moreau, G. Aulagner. (2011) Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. Journal of Clinical Pharmacy and Therapeutics 36:1, 19-26
246
Gabriel N. Waterman, Ori Yellin, Regina A. Swift, Russell Mapes, Benjamin Eades, Emily Ackerman, James R. Berenson. (2011) A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Annals of Hematology 90:2, 193-200
247
Jacob P Laubach, Robert L Schlossman, Constantine S Mitsiades, Kenneth C Anderson, Paul G Richardson. (2011) Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Review of Hematology 4:1, 51-60
248
Ola Landgren, S. Vincent Rajkumar. (2011) Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future. Seminars in Hematology 48:1, 66-72
249
Slobodan Marjanovic, Dragana Stamatovic, Ljiljana Tukic, Olivera Tarabar, Marija Elez, Lavinika Madjaru, Bela Balint, Zeljka Tatomirovic, Nada Kuljic-Kapulica, Nebojsa Andjelkovic. (2011) Autologous stem cell transplantation in the treatment of multiple myeloma single center experience. Vojnosanitetski pregled 68:5, 387-392
250
Mohammad Shameem, Jamal Akhtar, Rakesh Bhargava, Zuber Ahmad, Ummul Baneen, Nafees Ahmad Khan. (2011) Lambda light chain multiple myeloma presenting as pleural mass. Respiratory Medicine CME 4:1, 12-14
251
Wei Zhou, Jingzi Hu, Haimei Tang, Da Wang, Xuefeng Huang, Chao He, Hongbo Zhu. (2011) Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors. BMC Cancer 11:1, 485
252
Meral Beksac, Rauf Haznedar, Tulin Firatli-Tuglular, Hakan Ozdogu, Ismet Aydogdu, Nahide Konuk, Gulsan Sucak, Işık Kaygusuz, Sema Karakus, Emin Kaya, Ridvan Ali, Zafer Gulbas, Gulsum Ozet, Hakan Goker, Levent Undar. (2011) Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. European Journal of Haematology 86:1, 16-22
253
Walter Lehmacher, Stephanie Wolff. (2011) Die Bedeutung von Head-to-Head-Studien für die versorgungsnahe klinische Forschung. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 105:9, 639-645
254
Hong Chang, Young Trieu, Xiaoying Qi, Nan N. Jiang, Wei Xu, Donna Reece. (2011) Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Leukemia Research 35:1, 95-98
255
Stefan Knop. (2011) Continuous Treatment in Multiple Myeloma – Ready for Prime Time?. Onkologie 34:8, 461-466
256
Alex Molassiotis, Barbara Wilson, Susan Blair, Tracy Howe, James Cavet. (2011) Living with multiple myeloma: experiences of patients and their informal caregivers. Supportive Care in Cancer 19:1, 101-111
257
Stephanie Stringer, Kolitha Basnayake, Colin Hutchison, Paul Cockwell. (2011) Recent Advances in the Pathogenesis and Management of Cast Nephropathy (Myeloma Kidney). Bone Marrow Research 2011, 1-9
258
Donna E. Reece, Dan Sullivan, Sagar Lonial, Ann F. Mohrbacher, Gurkamal Chatta, Chaim Shustik, Howard Burris, Karthik Venkatakrishnan, Rachel Neuwirth, William J. Riordan, Michael Karol, Lisa L. Moltke, Milin Acharya, Peter Zannikos, A. Keith Stewart. (2011) Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemotherapy and Pharmacology 67:1, 57-67
259
Meletios A. Dimopoulos, Maria-Victoria Mateos, Paul G. Richardson, Rudolf Schlag, Nuriet K. Khuageva, Ofer Shpilberg, Martin Kropff, Ivan Spicka, Antonio Palumbo, Ka Lung Wu, Dixie-Lee Esseltine, Kevin Liu, William Deraedt, Andrew Cakana, Helgi Van De Velde, Jesús F. San Miguel. (2011) Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European Journal of Haematology 86:1, 23-31
260
Masayuki Kikukawa. (2011) Hematological malignancies in the elderly. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 48:6, 622-625
261
Xuemei Li, Kezhong Zhang, Zihai Li. (2011) Unfolded protein response in cancer: the Physician's perspective. Journal of Hematology & Oncology 4:1, 8
262
S. Vincent Rajkumar. (2011) Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology 86:1, 57-65
263
Javier De La Rubia, Miguel A. Sanz. (2011) Treatment of multiple myeloma in the elderly: realities and hopes. Leukemia & Lymphoma 52:1, 9-14
264
Hye Jung Chang, Jae Hoon Lee, Young Rok Do, Sung-Hwa Bae, Jung-Lim Lee, Seung Hyun Nam, Sung-Soo Yoon, Soo-Mee Bang. (2011) A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma. The Korean Journal of Internal Medicine 26:4, 403
265
I. Charlot-Lambrecht, J.-H. Salmon, L. Gagneux-Lemoussu, P. Brochot, J.-P. Eschard. (2011) Myélome multiple. EMC - Appareil locomoteur 6:4, 1-12
266
Priscilla Segges, Esteban Braggio. (2011) Genetic Markers Used for Risk Stratification in Multiple Myeloma. Genetics Research International 2011, 1-4
267
A. J. Waxman, P. J. Mink, S. S. Devesa, W. F. Anderson, B. M. Weiss, S. Y. Kristinsson, K. A. McGlynn, O. Landgren. (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116:25, 5501-5506
268
S. Bringhen, A. Larocca, D. Rossi, M. Cavalli, M. Genuardi, R. Ria, S. Gentili, F. Patriarca, C. Nozzoli, A. Levi, T. Guglielmelli, G. Benevolo, V. Callea, V. Rizzo, C. Cangialosi, P. Musto, L. De Rosa, A. M. Liberati, M. Grasso, A. P. Falcone, A. Evangelista, M. Cavo, G. Gaidano, M. Boccadoro, A. Palumbo. (2010) Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116:23, 4745-4753
269
D. Chauhan, A. V. Singh, M. Aujay, C. J. Kirk, M. Bandi, B. Ciccarelli, N. Raje, P. Richardson, K. C. Anderson. (2010) A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116:23, 4906-4915
270
P. G. Richardson. (2010) Improving the therapeutic index in myeloma. Blood 116:23, 4733-4734
271
H. Avet-Loiseau. (2010) Ultra High-Risk Myeloma. Hematology 2010:1, 489-493
272
P. Sonneveld, J. L. M. Jongen. (2010) Dealing with Neuropathy in Plasma-Cell Dyscrasias. Hematology 2010:1, 423-430
273
Michele Cavo, Paola Tacchetti, Francesca Patriarca, Maria Teresa Petrucci, Lucia Pantani, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Elena Zamagni, Antonio Palumbo, Massimo Offidani, Paolo Corradini, Franco Narni, Antonio Spadano, Norbert Pescosta, Giorgio Lambertenghi Deliliers, Antonio Ledda, Claudia Cellini, Tommaso Caravita, Patrizia Tosi, Michele Baccarani. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. The Lancet 376:9758, 2075-2085
274
Paul G Richardson. (2010) A new standard of care in newly diagnosed multiple myeloma. The Lancet 376:9758, 2043-2044
275
James J. Driscoll, Roopa DeChowdhury. (2010) Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy. Targeted Oncology 5:4, 281-289
276
Jean-Luc Harousseau. (2010) Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010. Clinical Lymphoma Myeloma and Leukemia 10:6, 424-442
277
J.-L. Harousseau, A. Palumbo, P. G. Richardson, R. Schlag, M. A. Dimopoulos, O. Shpilberg, M. Kropff, A. Kentos, M. Cavo, A. Golenkov, M. Komarnicki, M.-V. Mateos, D.-L. Esseltine, A. Cakana, K. Liu, W. Deraedt, H. van de Velde, J. F. San Miguel. (2010) Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 116:19, 3743-3750
278
T Watanabe, K Nagase, M Chosa, K Tobinai. (2010) Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. British Journal of Cancer 103:10, 1580-1587
279
D Tan, Z Lao, Y Loh, H J Ng, C Chuah, G C Wong, M Koh, Y C Linn, L C Lim, S L Tien, L H Lee, Y T Goh, W Hwang. (2010) Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma. Bone Marrow Transplantation 45:11, 1625-1630
280
Paul G Richardson. (2010) Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma. The Lancet Oncology 11:11, 1014-1016
281
Meletios-Athanassios Dimopoulos, Evangelos Terpos. (2010) Lenalidomide: an update on evidence from clinical trials. Blood Reviews 24, S21-S26
282
Pierre Ronco, Emmanuelle Plaisier, Pierre Aucouturier. (2010) Ig-Related Renal Disease in Lymphoplasmacytic Disorders: An Update. Seminars in Nephrology 30:6, 557-569
283
Faith Davies, Rachid Baz. (2010) Lenalidomide mode of action: linking bench and clinical findings. Blood Reviews 24, S13-S19
284
Alessandro Gozzetti, Marzia Defina, Monica Bocchia, Alberto Fabbri, Elena Marchini, Ida Chitarrelli, Francesco Lauria. (2010) Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma. Leukemia Research 34:11, e288-e289
285
Michel Delforge, Joan Bladé, Meletios A Dimopoulos, Thierry Facon, Martin Kropff, Heinz Ludwig, Antonio Palumbo, Philip Van Damme, Jesús F San-Miguel, Pieter Sonneveld. (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. The Lancet Oncology 11:11, 1086-1095
286
Gareth Morgan. (2010) Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Blood Reviews 24, S27-S32
287
A. Lemy, M. Toungouz, D. Abramowicz. (2010) Bortezomib: a new player in pre- and post-transplant desensitization?. Nephrology Dialysis Transplantation 25:11, 3480-3489
288
Jesús San-Miguel, Joan Bladé. Multiple Myeloma. In: Postgraduate Haematology. Wiley-Blackwell, 2010:577-598.
289
M. A. Dimopoulos, E. Terpos. (2010) Multiple myeloma. Annals of Oncology 21:Supplement 7, vii143-vii150
290
C. S. Chim, A. K. W. Lie, E. Y. T. Chan, Y. Y. Leung, S. C. W. Cheung, S. Y. T. Chan, Raymond Liang, Y. L. Kwong. (2010) A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. Annals of Hematology 89:10, 1019-1027
291
Shi-Lun Chen, Bin Jiang, Lu-Gui Qiu, Li Yu, Yu-Ping Zhong, Wen Gao. (2010) Bortezomib Plus Thalidomide for Newly Diagnosed Multiple Myeloma in China. The Anatomical Record: Advances in Integrative Anatomy and Evolutionary Biology 293:10, 1679-1684
292
Caroline Pabst, Jozef Zustin, Frank Jacobsen, Tim Luetkens, Nicolaus Kröger, Georgia Schilling, Carsten Bokemeyer, Guido Sauter, Djordje Atanackovic, Andreas Marx. (2010) Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Experimental and Molecular Pathology 89:2, 175-181
293
María-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, Norma Gutiérrez, Ana-Isabel Teruel, Raquel de Paz, José García-Laraña, Enrique Bengoechea, Alejandro Martín, Joaquín Díaz Mediavilla, Luis Palomera, Felipe de Arriba, Yolanda González, Jose-Mariano Hernández, Ana Sureda, José-Luis Bello, Joan Bargay, Francisco-Javier Peñalver, José-María Ribera, María-Luisa Martín-Mateos, Ramón García-Sanz, María-Teresa Cibeira, María-Luisa Martín Ramos, María-Belén Vidriales, Bruno Paiva, María-Angeles Montalbán, Juan-José Lahuerta, Joan Bladé, Jesús-Fernando San Miguel. (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. The Lancet Oncology 11:10, 934-941
294
Daryl Tan, Gerrard Teoh, L.C. Lau, Alvin Lim, T.H. Lim, K.C. Yap, P. Premalatha, Z.T. Lao, Nelson Wee, Christine Choo, H.C. Wee, S. Su, Y.S. Lee, L.H. Lee, William Hwang, Y.T. Goh. (2010) An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. American Journal of Hematology 85:10, 752-756
295
S Vincent Rajkumar. (2010) Optimising bortezomib in newly diagnosed multiple myeloma. The Lancet Oncology 11:10, 909-910
296
Massimo Offidani, Pietro Leoni, Laura Corvatta, Claudia Polloni, Silvia Gentili, Anna Marina Liberati, Stefano Pulini, Alessandro Gozzetti, Stelvio Ballanti, Chiara Nozzoli, Antonio Palumbo. (2010) Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. Clinical Lymphoma Myeloma and Leukemia 10:5, 353-360
297
J. Mehta, M. Cavo, S. Singhal. (2010) How I treat elderly patients with myeloma. Blood 116:13, 2215-2223
298
Christopher Blackburn, Kenneth M. Gigstad, Paul Hales, Khristofer Garcia, Matthew Jones, Frank J. Bruzzese, Cynthia Barrett, Jane X. Liu, Teresa A. Soucy, Darshan S. Sappal, Nancy Bump, Edward J. Olhava, Paul Fleming, Lawrence R. Dick, Christopher Tsu, Michael D. Sintchak, Jonathan L. Blank. (2010) Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit. Biochemical Journal 430:3, 461-476
299
CL Bi, WJ Chng. Molecular Genetics of Multiple Myeloma. In: Encyclopedia of Life Sciences. John Wiley & Sons, Ltd, 2010.
300
E. C. Heher, N. B. Goes, T. R. Spitzer, N. S. Raje, B. D. Humphreys, K. C. Anderson, P. G. Richardson. (2010) Kidney disease associated with plasma cell dyscrasias. Blood 116:9, 1397-1404
301
Sundar Jagannath, Meletios A. Dimopoulos, Sagar Lonial. (2010) Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leukemia Research 34:9, 1111-1118
302
F. Gay, A. Palumbo. (2010) Multiple myeloma: management of adverse events. Medical Oncology 27:3, 646-653
303
G. Kobbe, I. Bruns, T. Schroeder, A. Czibere, J. Warnecke, N. Hieronimus, N. Safaian, M. Kondakci, C. Saure, U. Germing, R. Haas, R. Fenk. (2010) A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Annals of Oncology 21:9, 1898-1904
304
Fortunato Morabito, Massimo Gentile, Carla Mazzone, Sara Bringhen, Ernesto Vigna, Eugenio Lucia, Anna G. Recchia, Francesco D. Raimondo, Pellegrino Musto, Antonio Palumbo. (2010) Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs. European Journal of Haematology 85:3, 181-191
305
P. G. Richardson, E. Weller, S. Lonial, A. J. Jakubowiak, S. Jagannath, N. S. Raje, D. E. Avigan, W. Xie, I. M. Ghobrial, R. L. Schlossman, A. Mazumder, N. C. Munshi, D. H. Vesole, R. Joyce, J. L. Kaufman, D. Doss, D. L. Warren, L. E. Lunde, S. Kaster, C. DeLaney, T. Hideshima, C. S. Mitsiades, R. Knight, D.-L. Esseltine, K. C. Anderson. (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:5, 679-686
306
A. Palumbo, F. Davies, M. Kropff, J. Bladé, M. Delforge, F. Costa, R. Garcia Sanz, S. Schey, T. Facon, G. Morgan, P. Moreau. (2010) Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Annals of Hematology 89:8, 803-811
307
Taimur Sher, Kena C. Miller, George Deeb, Kelvin Lee, Asher Chanan-Khan. (2010) Plasma cell leukaemia and other aggressive plasma cell malignancies. British Journal of Haematology 150:4, 418-427
308
Patrizia Tosi, Elena Zamagni, Paola Tacchetti, Michela Ceccolini, Giulia Perrone, Annamaria Brioli, Maria Caterina Pallotti, Lucia Pantani, Alessandro Petrucci, Michele Baccarani, Michele Cavo. (2010) Thalidomide-Dexamethasone as Induction Therapy before Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma and Renal Insufficiency. Biology of Blood and Marrow Transplantation 16:8, 1115-1121
309
M Ri, S Iida, T Nakashima, H Miyazaki, F Mori, A Ito, A Inagaki, S Kusumoto, T Ishida, H Komatsu, Y Shiotsu, R Ueda. (2010) Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24:8, 1506-1512
310
A Dispenzieri, S Jacobus, D H Vesole, N Callandar, R Fonseca, P R Greipp. (2010) Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia 24:8, 1406-1411
311
Adam J. Waxman, Michael Kuehl, Arun Balakumaran, Brendan Weiss, Ola Landgren. (2010) Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future. Clinical Lymphoma Myeloma and Leukemia 10:4, 248-257
312
Monika Engelhardt, Martina Kleber, Josefina Udi, Ralph Wäsch, Andrew Spencer, Francesca Patriarca, StefAn Knop, Benedetto Bruno, Martin Gramatzki, Fortunato Morabito, Martin Kropff, Antonino Neri, Orhan Sezer, Rom Hajek, Donald Bunjes, Mario Boccadoro, Christian Straka, Michele Cavo, Aaron Polliack, Hermann Einsele, Antonio Palumbo. (2010) Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leukemia & Lymphoma 51:8, 1424-1443
313
Ajay Nooka, Charise Gleason, Sagar Lonial. (2010) Improving Induction Therapy in Multiple Myeloma. Current Hematologic Malignancy Reports 5:3, 119-128
314
Han Yixiang, Zhang Shenghui, Wu Jianbo, Yu Kang, Zhang Yu, Yin Lihui, Bi Laixi. (2010) Matrine induces apoptosis of human multiple myeloma cells via activation of the mitochondrial pathway. Leukemia & Lymphoma 51:7, 1337-1346
315
Noppacharn Uaprasert, Peter M. Voorhees, Nigel Mackman, Nigel S. Key. (2010) Venous thromboembolism in multiple myeloma: Current perspectives in pathogenesis. European Journal of Cancer 46:10, 1790-1799
316
Jonathan L. Kaufman, Ajay Nooka, Mark Vrana, Charise Gleason, L. Thompson Heffner, Sagar Lonial. (2010) Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma. Cancer 116:13, 3143-3151
317
Hongfeng Guo, Xin Zhou, Yuanqiang Jiang, Guohua Yang, Chao Sun, Yun Zhuang, Hongli Sun, Mize Lu, Xifeng Qian, Feng Chen, Jingjue Mao, Heng Chen, Jun Xia, Yunfeng Shen. (2010) Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: A Chinese experience. American Journal of Hematology 85:7, 499-501
318
Guido Cavaletti, Andrzej J. Jakubowiak. (2010) Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leukemia & Lymphoma 51:7, 1178-1187
319
Shaji Kumar. (2010) Treatment of newly diagnosed multiple myeloma: advances in current therapy. Medical Oncology 27:S1, 14-24
320
Massimo Offidani, Pietro Leoni, Laura Corvatta, Claudia Polloni, Silvia Gentili, Agnese Savini, Francesco Alesiani, Marino Brunori, Massimo Catarini, Giuseppe Visani, Arduino Samori, Maurizio Burattini, Riccardo Centurioni, Mauro Montanari, Paolo Fraticelli, Miriana Ruggieri, Sadia Falcioni, Piero Galieni. (2010) ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. European Journal of Haematology 84:6, 474-483
321
P. Moreau, C. Hulin. (2010) Les nouveaux médicaments du myélome. Oncologie 12:5-6, 353-361
322
Rachid Baz, Mehul Patel, Elizabeth Finley-Oliver, Daniel Lebovic, Mohamad A. Hussein, Kena C. Miller, Margaret Wood, Taimur Sher, Kelvin Lee, Asher A. Chanan-Khan. (2010) Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leukemia & Lymphoma 51:6, 1015-1019
323
Francesca Gay, Antonio Palumbo. (2010) Management of disease- and treatment-related complications in patients with multiple myeloma. Medical Oncology 27:S1, 43-52
324
Iñaki Sanz, F. Eun-Hyung Lee. (2010) B cells as therapeutic targets in SLE. Nature Reviews Rheumatology 6:6, 326-337
325
Sikander Ailawadhi, Aisha Masood, Taimur Sher, Kena C. Miller, Margaret Wood, Kelvin Lee, Asher Chanan-Khan. (2010) Treatment options for multiple myeloma patients with high-risk disease. Medical Oncology 27:S1, 53-61
326
Tatsuya Yoshida, Shigeru Kusumoto, Atsushi Inagaki, Fumiko Mori, Asahi Ito, Masaki Ri, Takashi Ishida, Hirokazu Komatsu, Shinsuke Iida, Fuminaka Sugauchi, Yasuhito Tanaka, Masashi Mizokami, Ryuzo Ueda. (2010) Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports. International Journal of Hematology 91:5, 844-849
327
Tiffany Richards, Donna Weber. (2010) Advances in treatment for relapses and refractory multiple myeloma. Medical Oncology 27:S1, 25-42
328
T. Helleday. (2010) Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 31:6, 955-960
329
Jordi Bruna, Esther Udina, Albert Alé, Jorge J. Vilches, Ann Vynckier, Johan Monbaliu, Lee Silverman, Xavier Navarro. (2010) Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Experimental Neurology 223:2, 599-608
330
C. La Vecchia, C. Bosetti, F. Lucchini, P. Bertuccio, E. Negri, P. Boyle, F. Levi. (2010) Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Annals of Oncology 21:6, 1323-1360
331
Jacob P. Laubach, Paul G. Richardson, Kenneth C. Anderson. (2010) The evolution and impact of therapy in multiple myeloma. Medical Oncology 27:S1, 1-6
332
Prashant Kapoor, Rafael Fonseca, S. Vincent Rajkumar, Shirshendu Sinha, Morie A. Gertz, A. Keith Stewart, P. Leif Bergsagel, Martha Q. Lacy, David D. Dingli, Rhett P. Ketterling, Francis Buadi, Robert A. Kyle, Thomas E. Witzig, Philip R. Greipp, Angela Dispenzieri, Shaji Kumar. (2010) Evidence for Cytogenetic and Fluorescence In Situ Hybridization Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies. Mayo Clinic Proceedings 85:6, 532-537
333
J. Blade, L. Rosinol, M. T. Cibeira, M. Rovira, E. Carreras. (2010) Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 115:18, 3655-3663
334
Brian G.M. Durie. (2010) Role of new treatment approaches in defining treatment goals in multiple myeloma – the ultimate goal is extended survival. Cancer Treatment Reviews 36, S18-S23
335
María-Victoria Mateos. (2010) Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treatment Reviews 36, S24-S32
336
, Yeo-Kyeoung Kim, Sang-Kyun Sohn, Jae-Hoon Lee, Deok-Hwan Yang, Joon-Ho Moon, Jae-Sook Ahn, Hyeoung-Joon Kim, Je-Jung Lee. (2010) Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Annals of Hematology 89:5, 475-482
337
Hagen S. Bachmann, Jürgen Novotny, Stephan Sixt, Peter Liebisch, Ulrich H. Frey, Ulrich Dührsen, Winfried Siffert, Holger Nückel. (2010) The G-Allele of the PSMA6−8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels. European Journal of Haematologyno-no
338
Ajita V. Singh, Michael A. Palladino, George Kenneth Lloyd, Barbara C. Potts, Dharminder Chauhan, Kenneth C. Anderson. (2010) Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. British Journal of Haematology 149:4, 550-559
339
Antonio Palumbo, S. Vincent Rajkumar. (2010) Multiple myeloma: chemotherapy or transplantation in the era of new drugs. European Journal of Haematology 84:5, 379-390
340
J.- L. Harousseau, M. Dreyling, . (2010) Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v155-v157
341
David Dingli, S. Vincent Rajkumar. (2010) How best to use new therapies in multiple myeloma. Blood Reviews 24:3, 91-100
342
Huaibao Feng, Gang Chen. (2010) Adaptive Choice of Group Sequential Boundary. Statistics in Biopharmaceutical Research 2:2, 199-219
343
Shaji Kumar. (2010) Multiple myeloma – current issues and controversies. Cancer Treatment Reviews 36, S3-S11
344
Pavel Nemec, Zuzana Zemanova, Henrieta Greslikova, Kyra Michalova, Hana Filkova, Jana Tajtlova, Dana Kralova, Renata Kupska, Jan Smetana, Marta Krejci, Ludek Pour, Lenka Zahradova, Viera Sandecka, Zdenek Adam, Tomas Buchler, Ivan Spicka, Evzen Gregora, Petr Kuglik, Roman Hajek. (2010) Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy. Biology of Blood and Marrow Transplantation 16:4, 548-554
345
Martin Kaiser, Britta Lamottke, Maren Mieth, Michael R. Jensen, Cornelia Quadt, Carlos Garcia-Echeverria, Peter Atadja, Ulrike Heider, Ivana von Metzler, Seval Türkmen, Orhan Sezer. (2010) Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. European Journal of Haematology 84:4, 337-344
346
Douglas W McMillin, Jake Delmore, Ellen Weisberg, Joseph M Negri, D Corey Geer, Steffen Klippel, Nicholas Mitsiades, Robert L Schlossman, Nikhil C Munshi, Andrew L Kung, James D Griffin, Paul G Richardson, Kenneth C Anderson, Constantine S Mitsiades. (2010) Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nature Medicine 16:4, 483-489
347
Pour Ludek, Svachova Hana, Adam Zdenek, Almasi Martina, Kralova Dana, Buchler Tomas, Kovarova Lucie, Krejci Marta, Michalek Jaroslav, Penka Miroslav, Vorlicek Jiri, Hajek Roman. (2010) Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. European Journal of Haematology 84:4, 332-336
348
, , E. Gunsilius, Johannes Drach. (2010) Austrian consensus recommendations for the treatment of patients with multiple myeloma. memo - Magazine of European Medical Oncology 3:1, 7-10
349
Alessandro Corso, Silvia Mangiacavalli, Marzia Varettoni, Cristana Pascutto, Patrizia Zappasodi, Mario Lazzarino. (2010) Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients. Leukemia Research 34:4, 471-474
350
Teresa Meenaghan, Michael O'Dwyer, Patrick Hayden, Amjad Hayat, Margaret Murray, Maura Dowling. (2010) Home administration of bortezomib: Making a difference to myeloma patients' lives. European Journal of Oncology Nursing 14:2, 134-136
351
Meletios A. Dimopoulos, Christine Chen, Efstathios Kastritis, Maria Gavriatopoulou, Steven P. Treon. (2010) Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia 10:2, 110-117
352
Ulrike Heider, Jessica Rademacher, Martin Kaiser, Lorenz Kleeberg, Ivana von Metzler, Orhan Sezer. (2010) Decrease in CD4+ T-Cell Counts in Patients With Multiple Myeloma Treated With Bortezomib. Clinical Lymphoma Myeloma and Leukemia 10:2, 134-137
353
P. Sonneveld. (2010) More force or more smart?. Blood 115:10, 1859-1860
354
Roser Velasco, Josep Petit, Victoria Clapés, Enric Verdú, Xavier Navarro, Jordi Bruna. (2010) Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. Journal of the Peripheral Nervous System 15:1, 17-25
355
R. Velasco, J. Bruna. (2010) Chemotherapy-induced peripheral neuropathy: An unresolved issue. Neurología (English Edition) 25:2, 116-131
356
H. Einsele, S. Knop, C. Straka. (2010) Fortschritte in der Behandlung von Patienten mit multiplem Myelom. Der Onkologe 16:3, 263-273
357
H. Ludwig, N. Zojer. (2010) Konventionelle Behandlung von Patienten mit multiplem Myelom. Der Onkologe 16:3, 274-281
358
R. Velasco, J. Bruna. (2010) Neuropatía inducida por quimioterapia: un problema no resuelto. Neurología 25:2, 116-131
359
Anuj Mahindra, Diana Cirstea, Noopur Raje. (2010) Novel therapeutic targets for multiple myeloma. Future Oncology 6:3, 407-418
360
(2010) Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications–2. Mayo Clinic Proceedings 85:2, 197-199
361
William I. Bensinger, Sundar Jagannath, Robert Vescio, Elber Camacho, Jeffrey Wolf, David Irwin, Gerardo Capo, Marti McKinley, Phyllis Potts, David H. Vesole, Amitabha Mazumder, John Crowley, Pam Becker, Jacqueline Hilger, Brian G.M. Durie. (2010) Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma. British Journal of Haematology 148:4, 562-568
362
R. J. Haynes, S. Read, G. P. Collins, S. C. Darby, C. G. Winearls. (2010) Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrology Dialysis Transplantation 25:2, 419-426
363
Sonia Cunningham, Sabeeha Muneer, Aarati Ranganathan, Marissa Shrader, James R. Berenson, Bruce Cheson, Jorge E. Cortés. (2010) The 51st Annual Meeting of the American Society of Hematology. Clinical Lymphoma Myeloma and Leukemia 10:1, 11-20
364
D. Chauhan, A. V. Singh, B. Ciccarelli, P. G. Richardson, M. A. Palladino, K. C. Anderson. (2010) Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115:4, 834-845
365
M. Roussel, P. Moreau, A. Huynh, J.-Y. Mary, C. Danho, D. Caillot, C. Hulin, C. Fruchart, G. Marit, B. Pegourie, P. Lenain, C. Araujo, B. Kolb, E. Randriamalala, B. Royer, A.-M. Stoppa, M. Dib, V. Dorvaux, L. Garderet, C. Mathiot, H. Avet-Loiseau, J.-L. Harousseau, M. Attal, . (2010) Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 115:1, 32-37
366
Michael Schaapveld, Otto Visser, Sabine Siesling, Cees G. Schaar, Sonja Zweegman, Edo Vellenga. (2010) Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989. European Journal of Cancer 46:1, 160-169
367
Hila Magen-Nativ, Ron Ram, Moshe Yeshurun, Anat Gafter-Gvili, Pia Raanani, Ofer Shpilberg. (2010) Total therapy-based treatment for multiple myeloma—a single center experience. Annals of Hematology 89:1, 53-59
368
Antonio Palumbo, Francesca Gay. (2010) Towards a new standard of care for patients with myeloma?. The Lancet Oncology 11:1, 3-4
369
Cristina Gasparetto, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, George Keogh, John P. Chute, Keith M. Sullivan, Rachel Neuwirth, Patricia H. Davis, Linda M. Sutton, Russell D. Anderson, Nelson J. Chao, David Rizzieri. (2010) “Short Course” Bortezomib plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Nontransplant Candidates in Patients with Previously Untreated Multiple Myeloma. Biology of Blood and Marrow Transplantation 16:1, 70-77
370
Se Ryeon Lee, Seok Jin Kim, Yong Park, Hwa Jung Sung, Chul Won Choi, Byung Soo Kim. (2010) Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma. The Korean Journal of Hematology 45:3, 183
371
Yang-Seon Yi, Joo-Seop Chung, Moo-Kon Song, Ho-Jin Shin, Young-Mi Seol, Young-Jin Choi, Goon-Jae Cho, Gyeong-Won Lee, Joon-Ho Moon, In-Hye Hwang, Kang-Hee Ahn, Hee-Sun Lee, Kyung-Hwa Shin, Jong-Min Hwang. (2010) The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma. The Korean Journal of Hematology 45:3, 188
372
Isabelle Azaïs, Rachel Brault, Françoise Debiais. (2010) Nouvelles thérapies du myélome. Revue du Rhumatisme 77:1, 21-27
373
Isabelle Azaïs, Rachel Brault, Françoise Debiais. (2010) New treatments for myeloma. Joint Bone Spine 77:1, 20-26
374
S Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, Rafael Fonseca, David H Vesole, Michael E Williams, Rafat Abonour, David S Siegel, Michael Katz, Philip R Greipp. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology 11:1, 29-37
375
Rajeev Raghavan, Abdallah Jeroudi, Katafan Achkar, A. Osama Gaber, Samir J. Patel, Abdul Abdellatif. (2010) Bortezomib in Kidney Transplantation. Journal of Transplantation 2010, 1-6
376
Monique A. Hartley-Brown, Daniel M. Sullivan, Rachid Baz. (2010) State-of-the-Art Management of Complications of Myeloma and Its Treatment. Advances in Hematology 2010, 1-8
377
A. K. Stewart, P. G. Richardson, J. F. San-Miguel. (2009) How I treat multiple myeloma in younger patients. Blood 114:27, 5436-5443
378
C. F. de Larrea, M. T. Cibeira, M. Elena, J. I. Arostegui, L. Rosinol, M. Rovira, X. Filella, J. Yague, J. Blade. (2009) Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood 114:24, 4954-4956
379
Meletios A. Dimopoulos, Evangelos Terpos. (2009) Hematology: First-line bortezomib benefits patients with multiple myeloma. Nature Reviews Clinical Oncology 6:12, 683-685
380
Shaji K. Kumar, Joseph R. Mikhael, Francis K. Buadi, David Dingli, Angela Dispenzieri, Rafael Fonseca, Morie A. Gertz, Philip R. Greipp, Suzanne R. Hayman, Robert A. Kyle, Martha Q. Lacy, John A. Lust, Craig B. Reeder, Vivek Roy, Stephen J. Russell, Kristen E. Detweiler Short, A. Keith Stewart, Thomas E. Witzig, Steven R. Zeldenrust, Robert J. Dalton, S. Vincent Rajkumar, P. Leif Bergsagel. (2009) Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clinic Proceedings 84:12, 1095-1110
381
R Fonseca, P L Bergsagel, J Drach, J Shaughnessy, N Gutierrez, A K Stewart, G Morgan, B Van Ness, M Chesi, S Minvielle, A Neri, B Barlogie, W M Kuehl, P Liebisch, F Davies, S Chen-Kiang, B G M Durie, R Carrasco, Orhan Sezer, Tony Reiman, Linda Pilarski, H Avet-Loiseau. (2009) International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23:12, 2210-2221
382
Eirini Katodritou, Meletios A. Dimopoulos, Konstantinos Zervas, Evangelos Terpos. (2009) Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma. Cancer Treatment Reviews 35:8, 738-743
383
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
384
Robert A. Kyle, S. Vincent Rajkumar. (2009) Treatment of Multiple Myeloma: A Comprehensive Review. Clinical Cancer Reviews 3:1, 65-75
385
M A Dimopoulos, C Chen, A Spencer, R Niesvizky, M Attal, E A Stadtmauer, M T Petrucci, Z Yu, M Olesnyckyj, J B Zeldis, R D Knight, D M Weber. (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23:11, 2147-2152
386
Jean-Luc Harousseau. (2009) Integrating Novel Therapies in the Transplant Paradigm. The Cancer Journal 15:6, 479-484
387
Sigurdur Yngvi Kristinsson, Ola Landgren, Vincent S. Rajkumar. (2009) Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates. The Cancer Journal 15:6, 473-478
388
John D. Shaughnessy, Yiming Zhou, Jeff Haessler, Frits van Rhee, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Joshua Epstein, John Crowley, Bart Barlogie. (2009) TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. British Journal of Haematology 147:3, 347-351
389
J J Shah, R Z Orlowski. (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23:11, 1964-1979
390
Diana Cirstea, Sonia Vallet, Noopur Raje. (2009) Future Novel Single Agent and Combination Therapies. The Cancer Journal 15:6, 511-518
391
Ajay Nooka, Jonathan Kaufman, Sagar Lonial. (2009) The Importance of Complete Response in Outcomes in Myeloma. The Cancer Journal 15:6, 465-472
392
Jesus San-Miguel, M Victoria Mateos, Norma C. Gutierrez. (2009) Risk Stratification in the Era of Novel Therapies. The Cancer Journal 15:6, 457-464
393
Frank J. Bruzzese, Christopher A. Tsu, Jingya Ma, Huay-Keng Loke, Dongyun Wu, Zhi Li, Olga Tayber, Lawrence R. Dick. (2009) Development of a charcoal paper adenosine triphosphate:pyrophosphate exchange assay: Kinetic characterization of NEDD8 activating enzyme. Analytical Biochemistry 394:1, 24-29
394
K. Bauer, N. Skoetz, C. Brillant, C. Herbst, I. Monsef, S. Kluge, A. Engert. (2009) Tenth Biannual Report of the Cochrane Haematological Malignancies Group--Focus on Acute Myeloid Leukemia. JNCI Journal of the National Cancer Institute 101:20, E1-E1
395
R. L. Comenzo. (2009) How I treat amyloidosis. Blood 114:15, 3147-3157
396
J.-L. Harousseau, M. Attal, H. Avet-Loiseau. (2009) The role of complete response in multiple myeloma. Blood 114:15, 3139-3146
397
Raman Sood, Harry Carloss, Robert Kerr, Jose Lopez, Martin Lee, Mark Druck, Ian B. Walters, Stephen J. Noga. (2009) Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. American Journal of Hematology 84:10, 657-660
398
A Palumbo, O Sezer, R Kyle, J S Miguel, R Z Orlowski, P Moreau, R Niesvizky, G Morgan, R Comenzo, P Sonneveld, S Kumar, R Hajek, S Giralt, S Bringhen, K C Anderson, P G Richardson, M Cavo, F Davies, J Bladé, H Einsele, M A Dimopoulos, A Spencer, A Dispenzieri, T Reiman, K Shimizu, J H Lee, M Attal, M Boccadoro, M Mateos, W Chen, H Ludwig, D Joshua, J Chim, V Hungria, I Turesson, B G M Durie, S Lonial. (2009) International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23:10, 1716-1730
399
Jian Li, Dao-Bin Zhou, Li Jiao, Ming Hui Duan, Wei Zhang, Yong Qiang Zhao, Ti Shen. (2009) Bortezomib and Dexamethasone Therapy for Newly Diagnosed Patients With Multiple Myeloma Complicated by Renal Impairment. Clinical Lymphoma and Myeloma 9:5, 394-398
400
Sonia Cunningham, Sabeeha Muneer, Aarati Ranganathan, Bruce Cheson, Sundar Jagannath. (2009) The 45th Annual Meeting of the American Society of Clinical Oncology Orlando, FL; May 29 – June 2, 2009. Clinical Lymphoma and Myeloma 9:5, 345-352
401
Mark B. Meads, Robert A. Gatenby, William S. Dalton. (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nature Reviews Cancer 9:9, 665-674
402
Sundar Jagannath, Brian G. M. Durie, Jeffrey Lee Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Phyllis Potts, Afshin Eli Gabayan, Amitabha Mazumder, John Crowley, Robert Vescio. (2009) Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. British Journal of Haematology 146:6, 619-626
403
G Perrone, T Hideshima, H Ikeda, Y Okawa, E Calabrese, G Gorgun, L Santo, D Cirstea, N Raje, D Chauhan, M Baccarani, M Cavo, K C Anderson. (2009) Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23:9, 1679-1686
404
D. E. Reece, V. Sanchorawala, U. Hegenbart, G. Merlini, G. Palladini, J.-P. Fermand, R. A. Vescio, X. Liu, Y. A. Elsayed, A. Cakana, R. L. Comenzo, . (2009) Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 114:8, 1489-1497
405
M. Gertz. (2009) Finishing off fibrils. Blood 114:8, 1456-1457
406
Ivana von Metzler, Ulrike Heider, Maren Mieth, Britta Lamottke, Martin Kaiser, Christian Jakob, Orhan Sezer. (2009) Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. Experimental Cell Research 315:14, 2471-2478
407
Daniele Focosi. (2009) Bortezomib: The Subtle Line Between Drug-Induced Peripheral Neuropathy and Post-Herpetic Neuralgia. Clinical Lymphoma & Myeloma 9:4, E16-E17
408
Meletios A. Dimopoulos, Maria Roussou, Maria Gavriatopoulou, Flora Zagouri, Magdalini Migkou, Charis Matsouka, Despina Barbarousi, Dimitrios Christoulas, Erasmia Primenou, Irini Grapsa, Evangelos Terpos, Efstathios Kastritis. (2009) Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. Clinical Lymphoma & Myeloma 9:4, 302-306
409
Robert A. Kyle, S. Vincent Rajkumar. (2009) Treatment of Multiple Myeloma: A Comprehensive Review. Clinical Lymphoma & Myeloma 9:4, 278-288
410
T. Hideshima, H. Ikeda, D. Chauhan, Y. Okawa, N. Raje, K. Podar, C. Mitsiades, N. C. Munshi, P. G. Richardson, R. D. Carrasco, K. C. Anderson. (2009) Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells. Blood 114:5, 1046-1052
411
S. Lonial. (2009) Risky business in myeloma. Blood 114:3, 496-497
412
P. Kapoor, S. Kumar, R. Fonseca, M. Q. Lacy, T. E. Witzig, S. R. Hayman, A. Dispenzieri, F. Buadi, P. L. Bergsagel, M. A. Gertz, R. J. Dalton, J. R. Mikhael, D. Dingli, C. B. Reeder, J. A. Lust, S. J. Russell, V. Roy, S. R. Zeldenrust, A. K. Stewart, R. A. Kyle, P. R. Greipp, S. V. Rajkumar. (2009) Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 114:3, 518-521
413
D. Reece, K. W. Song, T. Fu, B. Roland, H. Chang, D. E. Horsman, A. Mansoor, C. Chen, E. Masih-Khan, Y. Trieu, H. Bruyere, D. A. Stewart, N. J. Bahlis. (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114:3, 522-525
414
Marc S Raab, Klaus Podar, Iris Breitkreutz, Paul G Richardson, Kenneth C Anderson. (2009) Multiple myeloma. The Lancet 374:9686, 324-339
415
Donna E Reece. (2009) Recent trends in the management of newly diagnosed multiple myeloma. Current Opinion in Hematology 16:4, 306-312
416
Marcio Nucci, Elias Anaissie. (2009) Infections in Patients With Multiple Myeloma. Seminars in Hematology 46:3, 277-288
417
C B Reeder, D E Reece, V Kukreti, C Chen, S Trudel, J Hentz, B Noble, N A Pirooz, J E Spong, J G Piza, V H J Zepeda, J R Mikhael, J F Leis, P L Bergsagel, R Fonseca, A K Stewart. (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23:7, 1337-1341
418
Harousseau , Jean-Luc , Moreau , Philippe , . (2009) Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine 360:25, 2645-2654
Full Text419
Edward A. Stadtmauer, Donna M. Weber, Ruben Niesvizky, Andrew Belch, Miles H. Prince, Jesús F. San Miguel, Thierry Facon, Marta Olesnyckyj, Zhinuan Yu, Jerome B. Zeldis, Robert D. Knight, Meletios A. Dimopoulos. (2009) Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. European Journal of Haematology 82:6, 426-432
420
James R. Berenson, Ori Yellin, Donald Woytowitz, Marshall S. Flam, Alan Cartmell, Ravi Patel, Herb Duvivier, Youram Nassir, Benjamin Eades, Christina DiLauro Abaya, Jacqueline Hilger, Regina A. Swift. (2009) Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. European Journal of Haematology 82:6, 433-439
421
E Kastritis, K Zervas, A Symeonidis, E Terpos, S Delimbassi, N Anagnostopoulos, E Michali, A Zomas, E Katodritou, D Gika, A Pouli, D Christoulas, M Roussou, Z Kartasis, T Economopoulos, M A Dimopoulos. (2009) Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 23:6, 1152-1157
422
Sagar Lonial, Jamie Cavenagh. (2009) Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. British Journal of Haematology 145:6, 681-708
423
James R. Berenson. (2009) Hematology: Bortezomib in newly diagnosed multiple myeloma. Nature Reviews Clinical Oncology 6:5, 255-256
424
Monique P. Curran, Kate McKeage. (2009) Bortezomib. Drugs 69:7, 859-888
425
J.-L. Harousseau, M. Dreyling, . (2009) Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv97-iv99
426
E. M. Ocio, P. Maiso, X. Chen, M. Garayoa, S. Alvarez-Fernandez, L. San-Segundo, D. Vilanova, L. Lopez-Corral, J. C. Montero, T. Hernandez-Iglesias, E. de Alava, C. Galmarini, P. Aviles, C. Cuevas, J. F. San-Miguel, A. Pandiella. (2009) Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 113:16, 3781-3791
427
Michel Attal, Jean-Luc Harousseau. (2009) The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents. Seminars in Hematology 46:2, 127-132
428
Eliot C. Heher, Thomas R. Spitzer, Nelson B. Goes. (2009) Light Chains: Heavy Burden in Kidney Transplantation. Transplantation 87:7, 947-952
429
Hiroto Ohguchi, Tomohiro Sugawara, Izumi Ishikawa, Mitsutaka Okuda, Yasuo Tomiya, Joji Yamamoto, Yasushi Onishi, Minami Fujiwara Yamada, Kenichi Ishizawa, Junichi Kameoka, Hideo Harigae. (2009) A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: β2-microglobulin associated with time to progression. International Journal of Hematology 89:3, 342-347
430
Marielle J Wondergem, Katrien Grünberg, Bart P H Wittgen, Pieter Sonneveld, Sonja Zweegman. (2009) Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment. Histopathology 54:5, 631-633
431
Thierry Facon, Jesus San Miguel, Maria Victoria Mateos, Cyrille Hulin. (2009) Frontline Treatment in Elderly Patients With Multiple Myeloma. Seminars in Hematology 46:2, 133-142
432
Charles Eby. (2009) Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. British Journal of Haematology 145:2, 151-163
433
Evangelos Terpos, M. Teresa Cibeira, Joan Blade, Heinz Ludwig. (2009) Management of Complications in Multiple Myeloma. Seminars in Hematology 46:2, 176-189
434
Sonia Cunningham, Sabeeha Muneer, Sundar Jagannath, Brad Kahl. (2009) Meeting Highlights from: The 50th Annual Meeting of the American Society of Hematology; San Francisco, CA; December 6–9, 2008. Clinical Lymphoma and Myeloma 9:2, 124-132
435
Rakesh Popat, Heather Oakervee, Catherine Williams, Mark Cook, Charles Craddock, Supratik Basu, Charles Singer, Stephen Harding, Nicola Foot, Simon Hallam, Liz Odeh, Simon Joel, Jamie Cavenagh. (2009) Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. British Journal of Haematology 144:6, 887-894
436
J. Drach. (2009) Novel therapeutic concepts in multiple myeloma. memo - Magazine of European Medical Oncology 2:S1, 5-9
437
Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, Edward A. Stadtmauer, Thierry Facon, Jean-Luc Harousseau, Dina Ben-Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna Reece, Joan Bladé, Mario Boccadoro, Jamie D. Cavenagh, Anthony L. Boral, Dixie-Lee Esseltine, Patrick Y. Wen, Anthony A. Amato, Kenneth C. Anderson, Jesus San Miguel. (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. British Journal of Haematology 144:6, 895-903
438
A Palumbo, S V Rajkumar. (2009) Treatment of newly diagnosed myeloma. Leukemia 23:3, 449-456
439
Jame Abraham. (2009) Advances in multiple myeloma treatment: lenalidomide and bortezomib. Community Oncology 6:2, 53-55
440
Sattva S. Neelapu. (2009) Choosing treatment options in newly diagnosed patients with multiple myeloma. Community Oncology 6:2, 55-58
441
Francesca Patriarca, Maria T. Petrucci, Sara. Bringhen, Luca Baldini, Tommaso Caravita, Paolo Corradini, Alessandro Corso, Francesco Di Raimondo, Antonietta Falcone, Felicetto Ferrara, Fortunato Morabito, Pellegrino Musto, Massimo Offidani, Mario Petrini, Rita Rizzi, Gianpietro Semenzato, Patrizia Tosi, Angelo Vacca, Michele Cavo, Mario Boccadoro, Antonio Palumbo. (2009) Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. European Journal of Haematology 82:2, 93-105
442
Johannes Drach. (2009) Redefining Risk Using Cytogenetic Changes. Clinical Lymphoma and Myeloma 9, S9-S10
443
Robert Z. Orlowsk. (2009) New Proteasome Inhibitors. Clinical Lymphoma and Myeloma 9, S43-S44
444
Sabine Tricot, Céline Berthon, Marie-Dominique Venon, Julie Gay, Remy Dulery, Aldo M Roccaro, Teru Hideshima, Irene M Ghobrial, Thierry Facon, Xavier Leleu. (2009) Thalidomide in multiple myeloma in the elderly. Aging Health 5:1, 7-18
445
Ashley Hamilton, Paolo Gallipoli, Emma Nicholson, Tessa L Holyoake. (2009) Targeted therapy in haematological malignancies. The Journal of Pathologyn/a-n/a
446
Xiaoyi Dun, Zhengang Yuan, Weijun Fu, Chunyang Zhang, Jian Hou. (2009) Severe pulmonary complications after bortezomib treatment in multiple myeloma. Hematological Oncologyn/a-n/a
447
Morie A. Gertz, Irene Ghobrial, Jean Luc-Harousseau. (2009) Multiple Myeloma: Biology, Standard Therapy, and Transplant Therapy. Biology of Blood and Marrow Transplantation 15:1, 46-52
448
S. Vincent Rajkumar. (2009) Multiple Myeloma. Current Problems in Cancer 33:1, 7-64
449
A. Palumbo, F. Gay. (2009) How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology 2009:1, 566-577
450
Jacob P. Laubach, Constantine S. Mitsiades, Aldo M. Roccaro, Irene M. Ghobrial, Kenneth C. Anderson, Paul G. Richardson. (2009) Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leukemia & Lymphoma 50:5, 694-702
451
Karthik Venkatakrishnan, Michael Rader, Ramesh K. Ramanathan, Suresh Ramalingam, Eric Chen, William Riordan, William Trepicchio, Michael Cooper, Michael Karol, Lisa von Moltke, Rachel Neuwirth, Merrill Egorin, Gurkamal Chatta. (2009) Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug—drug interaction study. Clinical Therapeutics 31, 2444-2458
452
Asher Chanan-Khan, Kena C. Miller, Laurie Musial, Swaminathan Padmanabhan, Jihnhee Yu, Sikander Ailawadhi, Taimur Sher, Alice Mohr, Zale P. Bernstein, Maurice Barcos, Mehul Patel, Dan Iancu, Kelvin Lee, Myron S. Czuczman. (2009) Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukemia & Lymphoma 50:7, 1096-1101
453
M.S. Gordon. (2009) Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. Yearbook of Oncology 2009, 121-122
454
A. K. Stewart. (2009) Novel therapies for relapsed myeloma. Hematology 2009:1, 578-586
455
Bruce Ruggeri, Sheila Miknyoczki, Bruce Dorsey, Ai-Min Hui. The Development and Pharmacology of Proteasome Inhibitors for the Management and Treatment of Cancer. Elsevier, 2009:91-135.
456
(2008) Bortezomib plus Melphalan and Prednisone for Multiple Myeloma. New England Journal of Medicine 359:24, 2613-2614
Free Full Text457
María-Victoria Mateos. (2008) Role of bortezomib for the treatment of previously untreated multiple myeloma. Expert Review of Hematology 1:1, 17-28
458
Durie , Brian G.M. , . (2008) Treatment of Myeloma — Are We Making Progress?. New England Journal of Medicine 359:9, 964-966
Full Text459
Morie A. Gertz. (2008) New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression. Leukemia & Lymphoma 49:12, 2240-2245
- Letters
